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Animal  models  of  epilepsy  and  seizures,  mostly  involving  mice  and rats,  are  used to  understand  the
pathophysiology  of the  different  forms  of epilepsy  and  their  comorbidities,  to identify  biomarkers,  and  to
discover  new  antiepileptic  drugs  and  treatments  for comorbidities.  Such  models  represent  an  important
area  for  application  of  the  3Rs (replacement,  reduction  and reﬁnement  of  animal  use).  This  report  pro-
vides  background  information  and  recommendations  aimed  at minimising  pain,  suffering  and  distress
in rodent  models  of epilepsy  and  seizures  in order  to improve  animal  welfare  and optimise  the qualityRs
of  studies  in  this  area.  The  report  includes  practical  guidance  on principles  of  choosing  a model,  induc-
tion  procedures,  in vivo recordings,  perioperative  care,  welfare  assessment,  humane  endpoints,  socialnimal modelpilepsy
ouse
at
eﬁnement
eizure
housing,  environmental  enrichment,  reporting  of studies  and  data  sharing.  In addition,  some  model-
speciﬁc  welfare  considerations  are  discussed,  and  data  gaps  and  areas  for  further  research  are  identiﬁed.
The  guidance  is  based  upon  a systematic  review  of the  scientiﬁc  literature,  survey  of the  international
epilepsy  research  community,  consultation  with  veterinarians  and  animal  care  and  welfare  ofﬁcers,
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and  the  expert  opinion  and  practical  experience  of  the  members  of  a Working  Group  convened  by the
United  Kingdom’s  National  Centre  for the  Replacement,  Reﬁnement  and  Reduction  of Animals  in  Research
(NC3Rs).
C
1
1
r
w
e
G
S
a
m
e
a
r
e
2
a
s
t
a
(
o
o
i
f©  2015  The  Authors.  Published  by  Elsevier  B.V. This is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ontents
1. Introduction  .  . . . .  . . . . .  .  . . . .  . . .  . . . .  . . . .  . . .  . . . . . .  .  . . .  .  .  . .  .  .  . .  .  . . .  . . .  .  . . .  . . . . .  . . . . . .  . .  .  . . . .  . . . . . . .  .  . . . . . . .  . . . . . . .  .  . . . . . .  . . .  . . . . . . . . . .  .  .  . .  . .  .  . . .  . . . . . .  . . . . .  . . . 3
1.1.  Background  . .  .  . . .  . . . .  .  . . .  .  . . . . . . . . . .  . . .  .  .  . .  .  .  . .  .  . . . . . . .  . . . . . . .  .  . . . .  .  .  .  . . . . . .  .  . . . . . .  . . . . .  . . .  . . . .  . . .  . .  . . .  . . . .  .  . . . . . . . . . . .  .  .  . . .  .  . . . . . .  . . .  .  .  .  .  . .  .  .  .  .  . . 3
1.2.  Working  group  aims  and scope  . . .  . . . . . . .  . . . .  .  . . .  .  . . .  . . .  . . .  .  . .  . . .  . . . . . . .  . . .  . .  .  . . . .  . . .  . .  . . . . . .  . .  .  . . . .  .  . .  . . .  . . . .  . . . .  .  . . . . . .  .  . .  .  . .  . . .  .  . . . . . . .  . . . . . . . 4
1.3.  Report  audience  and  contents  . . .  . . . . . . . .  . . . .  . . . .  . . . . . .  .  . . . .  . . .  .  .  . .  .  . . . . .  . . .  . . . .  . .  . . . .  .  . . .  . . .  . .  . . . . .  .  . . .  . . . .  . . .  . . . . .  .  .  .  .  .  .  . . . . . .  . . . .  . .  .  .  . .  . . .  .  . . . . 4
1.4. Methodology  .  .  . . .  .  . . .  . . .  . . .  .  . . .  .  . . .  .  . . .  . . . . . . . . . . . .  . . .  .  . . . . . .  .  . . .  . . . .  . . .  . . . . .  .  . . . .  . . .  . . . . . .  .  . . . .  .  . . .  .  . . .  . . . .  . .  .  . . .  .  . . . . . .  .  . . . .  .  .  .  .  . .  .  . . . .  . . . . . . .  . . 4
1.5.  Limitations  of methodology  . . . . .  . . . .  . . .  .  . . .  . . . .  . . . .  .  . . . .  . .  .  . . .  .  . . . . . .  . . .  . . . . . .  . . . . .  . .  .  .  .  . .  . . .  .  . . . .  . . . . .  . .  . .  .  .  . . .  . . . .  . . . . .  .  .  .  . .  . . . . . .  . . . .  .  .  . .  . . .  . .  5
2.  Animal  models  used  in  epilepsy  research  . .  .  . . .  .  .  .  .  .  .  .  .  .  . .  . . . .  .  . . .  .  . . . . . . . .  . .  . . .  .  . .  . . . . .  . .  . . . .  .  . . .  . . . . .  . . . . . . . . . . . . .  .  . . .  . . . . . . .  . . . . . . .  . .  .  .  .  .  .  . .  .  .  .  .  .  . .  .  . 5
2.1.  Area  of  epilepsy  research  . .  . . . .  .  . .  .  .  . .  .  .  .  .  . . .  .  . . .  .  . . . .  . . .  . . . .  .  .  . . .  . . .  . . . . . . . . . . . .  .  . . .  . . . . . . . .  . . . . . . .  .  . .  . . . . .  . . . . .  . . . .  .  .  .  . . .  .  . . . . . .  .  . .  .  . .  . . .  . . .  . .  . . 5
2.2. Species  and  models  used  . .  .  .  . . .  .  . . . . . .  .  . . .  . . .  .  . . .  . . . .  . . . . . . . .  .  .  . . . . . . .  . . . . .  .  . .  .  . . . . .  . . . . .  . .  .  .  . . .  . . .  . . . . . .  .  . . . .  . . .  .  .  . . . .  .  . .  .  . .  . . . .  . . . . . .  .  .  . .  . .  .  .  .  . 5
2.3.  Choice  of  animal  model .  .  . . .  .  . . .  . . . . . . .  . . .  .  . . .  .  .  . .  .  . . .  .  .  . .  . . .  .  .  . . .  . . .  . . . . . . .  . . .  .  . .  . . .  . . .  .  . . . .  .  . . .  . . . .  .  . . . . . . . . . . .  . . . . .  . . .  .  .  .  .  . . . . . .  . . . .  . .  .  .  .  . .  . .  .  .5
3.  General  principles  for reﬁnement.  . . .  .  . . . .  . . .  . . . .  . . .  .  . . .  .  . . .  .  . . . . .  .  .  . . .  . . .  .  . . .  .  . . . . . .  . . .  . .  . . .  . . . .  .  . . . . . .  . . . . .  . .  .  . .  . . . .  .  . . . .  . . .  .  . . . . .  . .  .  .  . .  . . .  .  . .  . . . .  . .  . . .6
3.1.  Considerations  in  the choice  of animal  model  .  .  . . .  .  . . .  . . .  .  . . .  . .  . . . . . .  . . .  . . . .  . . .  . . . . .  . . .  . . .  . . . .  .  . . . .  . . .  . . . . .  .  . .  . . .  .  . . . .  . . . . . . . . . .  .  .  .  .  . .  . . .  . . . .  . . . 6
3.2.  Induction  procedures  . . .  .  . . . . . .  . . . .  . . .  .  . . .  .  .  . .  .  .  . .  .  . . .  . . .  .  .  . .  .  . . . . . . .  . . . . .  .  . . . .  . . . . .  . . . . . .  . . . . . . .  .  . . . .  . . .  . . . . . . .  . . .  . . . . . .  .  . . .  .  .  .  . . .  . . . . . .  . . . . .  .  . .  . 8
3.3.  In vivo  recordings  . . .  .  . . .  . . .  . . . .  . . . .  . . .  .  .  . .  .  . . .  .  . . .  . . . .  . . . . . . .  . . . . .  . . . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . . .  . .  .  . . .  .  .  . .  . . . . .  . . . . .  . . .  .  . . .  . . . .  . . . .  .  . .  .  . .  . . .  . . . . .  . . .  8
3.4.  Perioperative  care  . . . . . . . . . . . .  . . . .  . . .  .  . . .  . . . .  . . . . .  . . . . . .  .  . .  . . . . . . .  .  . . .  . . . . . . . . .  .  . .  . . .  . . . .  .  . . .  . . . .  .  . . . .  . . .  . . . . . . .  .  . . . . . . .  .  .  .  .  . . . . . .  . . . .  .  .  .  .  . .  .  . . . . .  9
3.5.  Welfare  assessment  . . . .  . . . .  . . .  .  . . .  . . . . . . .  . . . .  . . .  .  . . . .  .  . .  . . . .  . . .  .  . . .  .  .  .  . . . . . .  .  . . . . . .  . . . . . . .  .  . . . .  . . .  . .  .  . .  . . .  . .  .  .  . . .  .  . . . .  . . .  . . .  . . .  . .  .  .  . . . . . .  . . .  . .  . . 11
3.6.  Humane  endpoints  .  .  . . .  .  . .  .  . . .  . . .  .  . . . .  . . .  .  . . .  .  .  . .  . . . . . .  .  .  . . .  . . . .  .  . . . . .  . . . . . . . .  .  . . . .  . . . . .  . . .  . .  . . .  .  .  . . .  .  . .  . . . . .  .  .  .  . . .  .  .  . . . . . . . . .  .  . .  . .  .  .  . . . . . . .  .  . . . 12
3.7.  Social  housing  . .  .  . . .  .  . . .  . . .  .  . . .  .  . . .  . . . .  . . .  .  . . .  .  . .  .  .  . . .  . .  .  .  . . . .  . . .  .  . . . .  .  . . . .  . . .  . . . . . . .  . . .  . . . . .  . . .  . . . . .  . . .  . . .  . . .  .  . . .  .  .  .  .  . .  .  .  .  .  . .  . . . . . .  . .  . . .  . .  .  . . .  . . 13
3.8. Environmental  enrichment  . . . .  . . . . . . .  . . .  .  . . .  .  .  . .  .  . . .  . .  .  .  . . . .  . . .  . . .  . .  .  .  . . .  .  . . . .  . . .  . . . . . . . . . . .  .  .  . . . . .  .  . . . .  . .  .  . . . .  . . .  . . .  . . . . . .  .  . . .  .  .  .  . . . . . . .  .  . .  .  . .  14
3.9.  Reporting  and  data  sharing  .  . . .  . . .  .  .  . .  .  .  . .  .  . . .  .  . . . . . . .  . .  . . . . .  . . . .  . . .  .  .  .  . . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . .  . . . .  .  . . .  . . . .  .  . . . .  .  . . . .  . . . . . .  . . . .  .  . .  .  . .  . .  .  .  .  . .  . . 15
4.  Model-speciﬁc  welfare  considerations  .  . . .  .  . .  .  . . . . . . . . . . . . . . .  . . . .  . . .  . . . .  . . . .  . . .  . .  . . .  . . . . . . . . . . . . . .  . . . . .  . .  .  . . . . . .  .  . .  . . . .  .  . . . . .  .  . . .  .  .  .  . . .  .  . . . . . . .  . .  .  . . .  . . 15
4.1.  Models  dependent  on initial  SE .  . .  .  . . .  . . . .  . . .  .  . . .  .  . . .  . . . .  . .  .  .  . . . .  .  . .  . . .  . . . . . . . . .  .  . . . . . . .  .  . . . . . .  . . . . . . .  .  . . . .  . . . . . . .  . . .  .  .  . . .  .  .  .  . . .  .  . . . . . .  . . . . . . . .  . 18
4.2.  Models  not  involving  SE  . .  .  . . .  .  . .  . . . .  . . . . . . . .  . . .  .  . . .  .  . . . . . .  .  . . . .  . .  .  .  . . .  . .  .  . . . . . . .  . . . . . . . . . .  . . . . .  .  . .  .  . . .  .  . . .  . . .  .  .  .  .  . . .  .  .  .  . .  .  .  .  .  . . . . . . .  . . .  . .  .  .  .  .  .  . .  18
5.  Discussion  and  conclusions  .  . . .  .  . . . .  . . . . . . . . . .  . . . .  . . .  .  .  . .  .  . . .  .  . . .  .  . .  . . . . .  .  . .  . . .  . .  .  . . . .  . . .  . . . .  .  . .  . . . .  . . .  .  . . .  .  . . . .  . . .  . . . .  .  . .  . . . . . .  .  . . . .  .  .  . .  . . . . . . .  . .  . . . .  . .  19
5.1.  Data  gaps  and  future  research  .  .  . . .  .  . . .  . . .  .  . . .  . . . .  . . . .  . . .  . . . .  .  . . .  .  .  . . . .  . . .  . . . . . . . . . . .  . . .  . . . .  . . .  . .  . . .  . . . . .  .  . . . .  . . .  .  . . . . .  . .  .  .  .  .  . . . . .  .  . . . . . . .  .  .  .  .  .  .  19
5.2.  Recommendations  . . .  . . .  .  . . . .  . . .  .  . . .  .  . . .  . . . .  . . . .  . . . . . . .  . . .  .  . . . .  . . .  .  . . . . .  .  . . . . . .  .  .  . . .  . . .  . . . . . . .  .  . . .  .  . . . .  . . . . . . .  .  . . . . . .  . . .  . . . .  . . . . . .  .  . . .  . . .  .  .  . .  . . .  19
Conﬂict  of  interest  statement .  . .  .  . . . . . .  . . .  .  . . .  .  . . .  .  . . .  . . . .  . . . . . . .  . . . . . . .  .  .  . . .  . . .  . . .  . . . . . .  . . . . . . .  . . . . . . .  .  . . . .  . . .  . . . . .  . . .  .  . . . . .  .  . .  . .  . . . . . .  .  . . .  . .  .  . . .  . .  . .  . . . .20
Acknowledgements .  . . . . . .  . . . .  . . .  .  . . .  . . .  . . . .  . . .  .  . . .  .  . . .  .  . . .  . . .  .  . . .  .  . .  .  .  . . .  . .  .  . . . . .  .  . . . . . . . . . .  .  .  . . . . .  .  .  . . .  . . . . . . . .  .  . . . . . . . . . .  .  .  . . . . .  . .  .  .  .  .  . . .  .  . . . . .  . . . .  . .20
Appendix  A.  Supplementary  data  .  . . .  .  . . .  .  . .  .  . . . .  .  . . .  . .  .  .  . . . . . .  .  . . . .  . . . .  . . .  .  . . .  . . . .  . .  .  . . . . . .  .  . . .  . . . . .  . . . . . . . .  . .  . . .  .  . . . .  . . .  . .  .  .  . . . .  . . .  .  .  .  . . .  .  . . . . . .  .  . .  . . . .  .  21
References  .  . . . . . . .  . . .  . . .  .  . . . .  . . . .  . . .  . . . .  . . . . . . .  . . . .  . . . .  .  . . .  . . .  . . . .  .  . . . . . . .  .  . . . . . .  . . . . . . .  . . . . . . . .  . . . . . . .  .  . . .  . . .  .  . . .  . . .  .  . .  .  . . . .  .  .  .  .  .  .  .  .  .  . . . . .  .  . . .  .  . . .  .  .  . .  . 21
. Introduction
.1. Background
Epilepsy (see Glossary) is one of the most common serious neu-
ological diseases. It affects an estimated 1% of the population,
hich equates to about 60 million individuals worldwide (England
t al., 2012). Epilepsy patients experience debilitating seizures (see
lossary) associated with abnormal electrical activity in the brain.
eizures typically last tens of seconds to a few minutes, and usu-
lly are separated by prolonged interictal periods. Epilepsy does
ore than cause seizures, however: depending on the type of
pilepsy it may  be associated with increased mortality (Sillanpää
nd Shinnar, 2010), transient postictal behavioural changes and a
ange of comorbidities including cognitive impairments (Inostroza
t al., 2011), anxiety (Mazarati et al., 2009; Epps and Weinshenker,
013) and systemic effects. At least 15 different types of seizures
nd 30 epilepsy syndromes have been identiﬁed across the life-
pan (Berg et al., 2010). The diversity of clinical epilepsies has led
o classiﬁcation by the International League Against Epilepsy (Berg
nd Cross, 2010; Berg and Scheffer, 2011).
There remain many unresolved clinical issues in epilepsy
Baulac and Pitkänen, 2008; Galanopoulou et al., 2012). First, none
continue to experience seizures. In patients in whom seizures are
well controlled, drugs may  exert debilitating side effects and, in
some cases, refractoriness to their therapeutic effects may  develop.
Third, disease-modifying therapies are needed: antiepileptic drugs
do not prevent the progression of the disease, and there is a lack of
therapies that can ameliorate or prevent the associated cognitive,
neurological and psychiatric comorbidities, or the epilepsy-related
mortality.
There is an increased demand for animal models that adequately
recapitulate human epilepsy, to further understand the mecha-
nisms underlying epileptogenesis in the different forms of epilepsy
(Löscher and Brandt, 2010) and to develop therapies to prevent
the epileptogenic process, better treat comorbidities and treat drug
resistant epilepsy (Baulac and Pitkänen, 2008; Brooks-Kayal et al.,
2013). However, animal models of epilepsy and seizures, mostly
involving mice and rats, have the potential to cause pain, suffering,
distress and lasting harm1 to the animals involved. This can be as a
consequence of the method of induction of the epilepsy syndrome,
comorbidities and associated animal husbandry practices, acute or
chronic post-ictal sequelae and instrumentation, and procedures
for monitoring epileptiform activity. Hence such models are typ-
ically classiﬁed in legislation (e.g. the European Directive on the
protection of animals used for scientiﬁc purposes (2010/63/EU))f the anti-epileptic drugs in clinical use can prevent development
f epilepsy in cases where the precipitating epileptogenic event
s identiﬁable. Second, pharmacological therapy remains unsatis-
actory: one third of the patients treated with antiepileptic drugs 1 Herein referred to as harms.
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Table 1
Keywords used in the literature search relating to possible adverse effects and
reﬁnements in animal models of epilepsy.
Epilepsy terms
Convulsion; epilepsy; seizure; status epilepticus
Possible adverse effects Possible reﬁnements
Aggression; anxiety; dehydration;
excessive; ﬁghting; infection;
locomotor activity; pain; mortality;
weight loss
Analgesia; antibacterial; antibiotics;
enrichment; group housing; heating;
ﬂuids; food; post-operative care;
reﬁnement
Table 2
Levels of evidence and grades of recommendation. Table based upon a scheme pro-
posed previously (Prescott et al., 2010) and adapted from the National Institute for
Health and Care Excellence (NICE) guidelines (Eccles and Mason, 2001).
Level of
evidence
Type of evidence Grade of
recommendation
I+ Appropriately designed, controlled trials,
with a low risk of bias (e.g. objective
assessment of the data)
A
I  Appropriately designed, controlled trials
II+  Case-control or cohort studies, with a low
risk of bias (e.g. objective assessment of
the data)
B
II Case-control or cohort studies
III Case reports, case series C
IV  Expert opinion, formal consensus D K. Lidster et al. / Journal of Neu
s moderate or severe procedures; similar regulations apply else-
here. There is therefore a need for clear guidance on their use and
eﬁnement, in order to minimise any suffering, which is important
or ethical, scientiﬁc, and legal reasons.
.2. Working group aims and scope
The National Centre for the Replacement, Reﬁnement and
eduction of Animals in Research (NC3Rs) is a scientiﬁc organi-
ation established by the United Kingdom (UK) Government in
004 to lead the discovery and application of new technologies and
pproaches to replace, reduce and reﬁne the use of animals for sci-
ntiﬁc purposes. In 2013 the NC3Rs convened an expert Working
roup with the following terms of reference:
. To review and summarise current use of mammalian models of
epilepsy.
. To identify the animal welfare issues.
. To recommend opportunities for reﬁnement.
. To assess and balance the beneﬁts of epilepsy research against
the harms to the animals involved.
. To publish the deliberations of the Working Group in a peer-
reviewed paper and promote the group’s recommendations
within the international epilepsy research community.
Membership of the Working Group comprised neuroscientists,
eurologists, epileptologists, neuropathologists, neurosurgeons,
nimal welfare scientists and veterinarians from academia and
he pharmaceutical industry, with experience covering a range of
pilepsy research areas, including chronic and acute animal models.
It was not within the scope of the Working Group to iden-
ify opportunities for replacement of animal models of epilepsy;
hese have been discussed and published previously (Cunliffe et al.,
014). Nor did the Working Group investigate and assess the pre-
ictive value of the various animal models, since this overlaps with
he goal of the Joint International League Against Epilepsy (ILAE)
nd American Epilepsy Society (AES) Translational Research Task
orce to optimise and accelerate preclinical anti-epileptic therapy
Galanopoulou et al., 2013; Simonato et al., 2014). Most studies in
nimal seizure/epilepsy models are in post-weaned animals and
here is a natural bias towards these models. The Working Group
ecognises the impact that age can have on welfare issues and
here there is evidence or accepted best practice in pre-weaned
nimals, it has been included.
.3. Report audience and contents
The Working Group’s report provides background information
nd recommendations to give researchers, veterinarians, animal
are staff, regulators, and local ethical or animal care and use com-
ittees the tools to reﬁne the use of animal models of epilepsy and
eizures. The focus is rodent models, but many of the principles for
eﬁnement apply to other species. General principles are given in
ection 3. More detailed reﬁnements for commonly used models
re covered in Section 4. We  note that many major epilepsy groups
lready work to high ethical standards; our aim is to promote best
ractice as widely as possible.
.4. Methodology
The foundation of the Working Group’s report was a litera-
ure search conducted using the PubMed and Go3Rs databases and
ombinations of the keywords listed in Table 1. These keywords
ere also used to screen for information in the book Models of
eizures and Epilepsy (Pitkänen et al., 2006). Titles and abstractsof the papers retrieved from the search were reviewed for rele-
vance. Those not relevant to the aims of the Working Group were
excluded. Full text copies of 142 articles published between 1970
and 2014 were obtained and screened for information on adverse
effects and reﬁnements in animal models of epilepsy. The qual-
ity of the reported studies was assessed according to the criteria
in Table 2. A separate, smaller literature search was  conducted to
examine reporting of the use of analgesia in studies utilising rodent
models of epilepsy (see Section 3.4).
A qualitative survey was  conducted amongst researchers work-
ing with animal models of epilepsy identiﬁed from publications
in the ﬁeld. A questionnaire was  emailed to 322 researchers in 28
countries. Researchers were invited to participate anonymously in
the survey and asked to answer 12 questions (see Appendix 1),
with the aim to identify which mammalian models are used in
epilepsy research and to deﬁne best practice. The survey excluded
animals used for the generation of in vitro models of epilepsy and
seizures. There were three periods of data collection (July 2013,
November 2013 and March 2014). A total of 60 survey responses
covering a broad range of animal models were returned for anal-
ysis. This is a satisfactory response rate for a qualitative survey.
The survey responses represented a wide geographical distribution
with responses from 20 countries in Europe, North America, South
America, Asia and Australia.
In addition to the survey, between February and April 2014, KL
conducted interviews with the Named Veterinary Surgeons (NVS)
and Named Animal Care and Welfare Ofﬁcers (NACWO) at four UK
universities with research groups using rodent models of epilepsy.
The Working Group’s recommendations were graded according
to the levels of evidence deﬁned in Table 2, following the approach
previously adopted by Prescott et al. (2010). Recommendations
were graded (A–D) according to the highest level of evidence (I–IV).
Where there is direct supporting evidence, the individual reference
and level of evidence is indicated within the recommendation.
roscience Methods 260 (2016) 2–25 5
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Fig. 1. Areas of epilepsy research represented in the survey. Coloured bars are
representative of the number of respondents in the survey conducting research
in each area of epilepsy research: acute seizure models (blue), models of status
epilepticus (purple), focal epilepsy (red), and generalised epilepsy (green). Grey bars
are  representative of the number of publications in the scientiﬁc literature based
upon a PubMed search conducted using search terms detailed in Appendix 2. (The
search methods used may result in an overestimation of the number of publica-
tions representing a seizure type. For example, search results for “tonic” may  result
in  publications, which the primary aim of the study was not to investigate tonic
seizures but “tonic” may have been used in the abstract to describe features of other
types of (e.g. generalized tonic–clonic or focal tonic–clonic)). (For interpretation ofK. Lidster et al. / Journal of Neu
.5. Limitations of methodology
In general, there is a paucity of published information on both
he animal welfare implications of animal models of epilepsy and
pportunities for their reﬁnement. Where evidence was  lacking,
he Working Group based its recommendations on responses from
he survey and the expert opinion and practical experience of its
embers (Level IV evidence).
. Animal models used in epilepsy research
The survey enabled the Working Group to obtain an overview
f the current areas of epilepsy research, the types of animal model
sed and their limitations.
.1. Area of epilepsy research
To ensure the results of the survey were representative of the
pilepsy research community, researchers were asked in which
rea(s) of epilepsy research they worked; areas were divided into
cute seizures, focal epilepsy, generalised epilepsy, status epilepti-
us (SE) (see Glossary) and genetic models with epilepsy as part
f the phenotype. Survey responses were found to be broadly
epresentative of current epilepsy research areas reported in the
ublished literature (up to May  2015), with the exception of a
ew areas which were under-represented (e.g. tonic seizures) or
ver-represented (e.g. generalised tonic–clonic seizures and limbic
pilepsy) (Fig. 1, Appendix 2).
.2. Species and models used
Researchers were asked which animal model(s) they currently
sed and have previously used. A trend towards increased use of
ice was identiﬁed; increasing from 33% of total reports of ani-
als previously used to 49% of animals currently used (Fig. 2). This
s likely to be a reﬂection of the growing increase in availability
f genetically-modiﬁed mouse models; almost 400 genes associ-
ted with seizure phenotypes in mice are listed on the Jackson
aboratory database (http://www.jax.org/).
A trend towards decreased use of non-human primate models
as also identiﬁed. Published non-human primate models include
he macaque model of mesial TLE with kainic acid injection (Chen
t al., 2013), the marmoset model of TLE with pilocarpine injec-
ion (Perez-Mendes et al., 2011) and naturally-occurring epileptic
aboons (Szabó et al., 2012). Given the serious ethical and animal
elfare issues raised by the use of non-human primates2 in inva-
ive research, their use should be limited to cases where there is
trong justiﬁcation on scientiﬁc and/or medical grounds (Prescott,
010; Bateson et al., 2011).
An overview of the range of animal models reported in the
urvey, categorised into acute seizure models, chronic models
ith high propensity for induced seizures or epileptogenesis, and
hronic models of epilepsy, is presented in Table 3 (classiﬁcation
evised by Simonato et al., 2014).
Where researchers had ceased to use a particular rodent model,
hey were asked the reasons for this. In 57% of cases this was due to
 change in strategic direction, in 14% due to ﬁnancial reasons, and
n 11% due to lack of translation to the clinic. Other explanations
rovided included the severity of the model (7%) and its subsequent
urden on animal wellbeing, high mortality (3%) and high levels of
ariability in the model (1%).
2 For advice on reﬁning non-human primate use and care, see www.nc3rs.org.uk/
elfare-non-human-primates.the references to color in this ﬁgure legend, the reader is referred to the web version
of  this article.)
Researchers were asked the age of animals used. The age range
varied according to the model; for example, genetic models were
commonly used at very young ages (postnatal day 0 to postnatal
day 10). Commonly used induced models, such as kainic acid and
pilocarpine, varied from using young animals (postnatal day 10) to
adults. The variation in ages reﬂects the different aspects of epilepsy
and seizures being researched and technical considerations (e.g.
ease of patch clamping or calcium imaging).
2.3. Choice of animal model
Researchers were asked what factors they considered were lim-
itations on the choice of animal model (summarised in Fig. 3). High
mortality rates and variability between animals were the most
common limitations, along with high ﬁnancial cost. Note that many
of the limitations are related and have the potential to be addressed
6 K. Lidster et al. / Journal of Neuroscience Methods 260 (2016) 2–25
Table 3
Animal models reported in survey (table format adapted from Simonato et al., 2014).
Acute seizure models Chronic models of high propensity for induced seizures or epileptogenesis
Electrical Chemical Genetic Induced
6 Hz simulation Gamma-hydroxybutyrate (GHB) D2R knockout Kindling (corneal, hippocampal, amygdaloidal, PTZ)
Maximal Electroshock Seizure (MES) Pentylenetetrazole (PTZ) En2 knockout Hypoxia and/or ischemia
Models of epilepsy
Genetic Induced
Electrical Chemical CNS insult
5-HT2c knockout
DBA/2 mice
Genetic Absence Epilepsy Rats from
Strasbourg (GAERS)
Genetic benign familial neonatal-infantile
seizures (BFNI)
Genetic generalised epilepsy with febrile
seizures (GEFS)
Kcna1-null mouse
Lethargic
LGI1 knockout
NaV 1.1 knockout
Stargazer
Scn1a knockin
Sv2a knockout
Tottering
TGF and TGFR transgenic
Wistar Albino Glaxo Rats from Rijswijk
(WAG/RiJ)
Amygdala stimulation
Perforant path stimulation
Cobalt cortical
Kainic acid (intraamygdala,
intrahippocampal, intraperitoneal,
subcutaneous)
Lithium-pilocarpine
Pilocarpine
Penicillin
Tetanus toxin
Albumin
Blood brain barrier
disruption
Fluid percussion (traumatic
brain injury)
Hypoxia
Hypoxic-ischemic
encephalopathy
Maternal teratogen model
of autism and epilepsy
Stroke
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cig. 2. Species of epilepsy models reported in the survey. Other species includes
aturally-occurring epilepsy in cats, dogs, pigeons and pigs.y taking advantage of the reﬁnement opportunities highlighted in
his report.
Researchers were asked “Do you think the limitations of ani-
al  models are restricting progress in epilepsy research?” 48% of
0% 10% 20% 30% 40%
Regulatory ap proval
Large group  si zes
Animal welfare
Labo ur intensive
High financi al costs
High variability
High mortality
Strongly  agree Agre e Neither agree  or  
ig. 3. Limitations on choice of animal model. Reasons provided by survey respondents i
hoice of animal model?”.researchers considered that they were restricting progress, 27%
considered that they were not, and 25% were unsure. One reason
given for the former view was difﬁculty in recapitulating speciﬁc
aspects of the human condition. Re-assessment of translational
approaches is currently being undertaken by the ILAE/AES Trans-
lational Research Task Force (Galanopoulou et al., 2013; Simonato
et al., 2014).
3. General principles for reﬁnement
The literature search, survey and interviews identiﬁed a range
of reﬁnement opportunities which are described below, supple-
mented by the expert opinion and professional experience of the
Working Group members.
3.1. Considerations in the choice of animal model
The choice of model will depend on the type of epilepsy being
modelled, the scientiﬁc question being asked, and the need to min-
imise animal suffering and numbers (Pitkänen et al., 2006; Grone
and Baraban, 2015). Models should represent key features of the
corresponding disease, but should not necessarily strive to be iden-
tical. For instance, testing methods to control seizures may  need a
 50% 60% 70% 80% 90% 100%
dis agree Di sagree Strongly  di sagree
n response to Question 9. “Do you consider the following to be limitations on your
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igher rate of seizures than that which occurs in the typical clini-
al disease, because testing a decrease from extremely low rates is
mpractical in the current scientiﬁc settings and timelines.
Models can be distinguished between acute and chronic, focal
nd generalised, acquired and genetic. Acute animal models use
hemical, electrical or physical stimulation to trigger epileptic
ctivity and have been extensively used to discover new drugs
ut they have not led to the development of drugs that target
ither the generation or the maintenance of the epileptic state.
cute animal models model symptomatic seizures in normal brain,
hile chronic epilepsy results from pathological structural and
unctional changes in the brain. Chronic models have been recom-
ended for many kinds of epilepsy research (Stables et al., 2003)
ncluding screening systems (e.g. NIH Anticonvulsant Screening
rogram (www.ninds.nih.gov/research/asp/index.htm) and target
alidation or proof-of-pharmacology for mechanisms that cannot
e tested with acute seizure models (i.e. anti-inﬂammatory thera-
ies) (Löscher et al., 2013).
Behavioural comorbidities observed in the interictal period (e.g.
ognitive impairments, hyperactivity and depression (Barkmeier
nd Loeb, 2009; Tabb et al., 2007)) are an integral part of the
pilepsy syndrome and legitimate subjects for investigation. How-
ver they may  also impact on the animals’ welfare, in which case
esearchers and ethical oversight committees must carefully weigh
he potential research beneﬁts and the harms to the animals. A
oadmap for rational selection, implementation and interpretation
f behavioural assays in animal models of epilepsy has previously
een deﬁned (Heinrichs and Seyfried, 2006).
One of the major welfare concerns for those working with ani-
al  models of epilepsy is the experience of the animal during and
etween seizures. It can be difﬁcult to appreciate the experience
f animals during seizures; the only surrogate is the experience of
pilepsy patients. It is important to realise that the experience of
itnesses can be very different from that of the patients (e.g. con-
ulsions can be very distressing to witness, but since the person
aving the convulsion has markedly reduce levels of conscious-
ess, they experience no distress during the seizure, Englot et al.,
010). Observations in rats have shown depressed cortical function
uring focal seizures (Englot et al., 2008); reﬁnement of the choice
f model solely on the frequency or intensity of seizure activity
ay  not be appropriate. The priority should be to objectively assess
he experience of the animal and think critically about what is the
elevant model for the speciﬁc research question and the clinical
elevance. Increasingly more sophisticated approaches to assessing
dverse effects (e.g. pain, distress, anxiety) in laboratory rodents
re being developed and research teams should be adopted when
ossible (e.g. by searching the literature and NC3Rs website www.
c3rs.org.uk).
Assessment of animal welfare, and balancing harms to animals
gainst the potential beneﬁts of the research, must address the
hole epilepsy syndrome, not just one of the clinical signs. The
eriods between seizures are essential for animals to maintain
hemselves in good condition and allow recovery from seizures.
he recurring episodic nature of epilepsy, and the repeated proto-
ols that may  be used to induce the epileptic state, means that the
requency of adverse effects, as well as their intensity and duration,
ust be included in the harm-beneﬁt analysis. A judgment needs
o be made about what is acceptable in terms of the type, duration,
ntensity and frequency of seizures, recovery time and the level of
uffering following the initiation of seizures.Recommendations:
. A search of the scientiﬁc literature should be carried out to
ensure the animal model chosen is scientiﬁcally relevant, thence Methods 260 (2016) 2–25 7
least severe model for the scientiﬁc purpose, and that any model-
speciﬁc reﬁnement opportunities are identiﬁed (Grade D).
2. Assessment of the harms to animals and balancing these against
the potential beneﬁts of the research, should take account of
the lifetime experience of the animals and the whole epilepsy
syndrome (not just seizures). The greater the animal welfare
cost, the greater the strength of justiﬁcation needed in terms
of scientiﬁc and/or medical beneﬁt (Grade D).
Choice of strain:  Rodent models are used for studying the cel-
lular and neural network mechanisms underlying epilepsy. Rodent
strains can differ in seizure susceptibility (McKhann et al., 2003;
McLin and Steward, 2006; Frankel, 2009; Schauwecker, 2011),
effects of antiepileptic drugs (Leclercq and Kaminski, 2014), as well
as the consequences of seizure activity (Schauwecker, 2011). For
example, the use of C57BL/6 is hampered by its low sensitivity
to seizure induction (Müller et al., 2009; Bankstahl et al., 2012);
a problem addressed by back-crossing with other strains. Mouse
genetic backgrounds play a crucial role in genetically-modiﬁed
phenotypes and the susceptibility of these strains to seizures and
neuropathological consequences (Schauwecker, 2011). It is, thus,
important to ensure that the genetic background is controlled to
avoid ‘genetic’ drift and appropriate wild-type littermate controls
are generated from the same colony.
Choice of breeder: When obtaining animals from commercial
breeders, the choice of the breeder is a critical factor. It was recently
demonstrated that adult female Wistar rats from different breeders
vary in anxiety-like behaviour, seizure susceptibility and epilepto-
genesis in the kindling model of temporal lobe epilepsy (Honndorf
et al., 2011). A higher mortality rate after pilocarpine injection was
observed in C57BL/6 mice depending on the supplier (Borges et al.,
2003). Decisions about appropriate commercial colonies used for
biomedical research should, therefore, be taken with care.
Choice of age: Seizure susceptibility and manifestation of
epilepsies can be age-dependent. Some types of seizures and
epilepsies occur in neonates and infants and are not present in
adults (Maresˇ, 2012; Wasterlain et al., 2013) or vice versa (Sperber
et al., 1999). Since brain function alters during development
(e.g. neurotransmission, neuronal properties and connectivity
(Galanopoulou and Moshe, 2011), the age of animals is likely
to affect many factors such as sensitivity to chemoconvulsants
(Wozniak et al., 1991) and kindling (Cilio et al., 2003), seizure
latency and intensity (Pierson and Swann, 1988; Thompson et al.,
1991), mortality (Blair et al., 2009) and behavioural, patho-
physiological and pharmacological responses to anticonvulsant
(Stafstrom et al., 1993; Shetty et al., 2012; Maresˇ, 2014).
Choice of sex: Gender differences are emerging amongst
some types of epilepsies (Galanopoulou, 2014). Females are more
susceptible to epilepsies such as juvenile myoclonic epilepsy
(Camﬁeld and Camﬁeld, 2009) and childhood absence epilepsy
(Panayiotopoulos, 2007) whilst males are more susceptible to West
or Dravet syndrome and childhood epilepsy with centrotemporal
spikes (Panayiotopoulos, 2007).
Sex hormones may  also inﬂuence the timing and frequency
of certain seizures, as occurs in catamenial epilepsy (Koppel
and Harden, 2014). In animal models involving immature and
adult animals, sex hormones and neurosteroids affect signalling
pathways and brain regions regulating seizure initiation and
maintenance (Scharfman and MacLusky, 2014). The expression of
function of numerous signalling pathways and the anatomy, con-
nectivity or function of brain networks involved in seizure control
also exhibit sex differences that may  affect the susceptibility to
seizures, their consequences or response to drugs (Giorgi et al.,
2014; Akman et al., 2015). Antiepileptic drug targets as well as
pharmacokinetic and adverse effects of antiepileptic drugs may
be affected by gender (Perucca et al., 2014; Pitkänen et al., 2014).
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ost preclinical studies are performed on adult males (Pitkänen
t al., 2014), possibly due to the confounding contributions of the
estrus cycle on seizure susceptibility (Scharfman et al., 2005); but
here are plans to address the imbalance of sex across biomedical
esearch (Clayton and Collins, 2014).
Recommendations:
. Variations in the strain, genetic background, source, age and sex
of animals can inﬂuence seizure susceptibility and mortality (e.g.
Grade B for strain; Schauwecker, 2011, Level II; Grade A for age:
Thompson et al., 1991, Level I, Pierson and Swann, 1988, Level I+;
Grade A for sex; Scharfman and MacLusky, 2014, Level II; Grade
A for source; Borges et al., 2003, Level I). The variability should be
taken into consideration when designing and conducting studies
and adequate measures taken to reduce experimental bias. The
strain, source, age and sex of animals used in studies should be
consistent, and reported in publications.
. If using genetically-modiﬁed mice, the genetic background
should be controlled for and appropriate littermate controls with
the same genetic background should be used; for example, use
age-matched wild-type littermates as controls (Grade A; Bourdi
et al., 2011, Level I).
. Given the evidence for sex-speciﬁc effects on epileptogenesis,
consideration should be given to using animals of both sexes.
If females are used, the impact of the oestrus cycle on seizure
susceptibility needs to be considered (Grade A; Scharfman et al.,
2005, Level I).
.2. Induction procedures
Procedures leading to the induction of seizures and/or epilepsy
hould be tailored to reach the scientiﬁc endpoint effectively whilst
imiting suffering and mortality. The survey reﬂects the impor-
ance of the induction period, which showed of the 31 respondents
eporting high mortality as an adverse effect, 90% (28/31) reported
igh mortality during the induction phase.
The status-inducing agent, its dose, its route of administration
nd SE duration all can affect both mortality and reliability of pro-
ression to chronic epilepsy, as discussed in more detail in Curia
t al. (2008). It is important to determine a balance between min-
mising mortality and inducing the chronic epilepsy model. More
etail on reﬁnement of speciﬁc induction methods is given in Sec-
ion 4, Model-speciﬁc reﬁnements.
Long-term epilepsy studies investigating the efﬁcacy of anti-
pileptic drugs on spontaneous seizures may  require long-term
ontinuous administration of drug compounds. The choice of
elivery method should be chosen to allow effective drug concen-
ration levels (Löscher, 2007), whilst taking into consideration the
otential additional stress to the animal. The advantages and dis-
dvantages of different routes of administration of anti-epileptic
rugs in rodents is summarised in Löscher, 2007. Reﬁnement of
he administration protocol, for example, administration of drug
rally in food or water provides a non-invasive, less stressful alter-
ative to repeated intraperitoneal injections and is more relevant
o the human situation (Grabenstatter et al., 2007; Ali et al., 2012).
For general advice on reﬁning procedures for the administra-
ion of substances to laboratory animals (e.g. consideration of the
hoice of route, dosing volume and frequency, and physiochemical
roperties of the substance) see Morton et al. (2001) and the NC3Rs-
unded Procedures with Care website3. Use of appropriate and
3 Procedures with Care offers practical advice on the manual skills required for
dministration of substances to mice and rats, including high-deﬁnition instruc-
ional videos: www.procedureswithcare.org.uk.nce Methods 260 (2016) 2–25
skilled handling techniques is essential to avoid anxiety and stress
responses in the animals, which can lead to defensive aggression,
difﬁculties in performing subsequent procedures and unwanted
variation in experimental data. Handling mice by the tail induces
aversion and high anxiety, to which mice do not readily habituate,
and generally should be avoided (Hurst and West, 2010; Gouveia
and Hurst, 2013).
Recommendations:
6. Procedures leading to the induction of seizures and/or epilepsy
should be tailored to reach the scientiﬁc objectives effectively
whilst minimising harms and mortality (Grade D).
7. Research personnel should be adequately trained and competent
in the manual skills for appropriate handling and restraint of
animals for the administration of substances. Picking up mice
by the tail should be avoided as this induces aversion and high
anxiety; animals should be picked up by a non-aversive method
(e.g. handling tunnels or cupping) (Grade A; Gouveia and Hurst,
2013), Level I+).
3.3. In vivo recordings
The diagnostic feature of epilepsy is recurring seizures which,
according to the ILAE deﬁnition, are due to abnormally exces-
sive and/or synchronous neuronal activity in the brain (Fisher
et al., 2005). Seizures are often associated with motor signs, which
provide end points for classical acute drug screening models such
as the high dose pentylenetetrazole (PTZ) and the maximal electro-
shock (MES) models, and for many acute measurements of seizure
susceptibility. Detecting spontaneous seizures in chronic models
needs long term recording. Several approaches are used, either
alone or in combination. Video recording or other measurements
such as micro-electro-mechanical systems (MEMS), can detect
movements associated with seizures (Sunderam et al., 2007). Auto-
mated observational systems (e.g. Van de Weerd et al., 2001)
can be used to analyse the behavioural proﬁle of animals fol-
lowing seizure induction (Riljak et al., 2014) and methods are
currently being developed to allow automated recordings in the
home cage environment4. Electrophysiological recording provides
more direct detection of seizures, and is particularly important for
those seizures with no or minimal motor consequences; video-
EEG monitoring should be used to identify seizures with no motor
symptoms (Arcieri et al., 2014). In addition to these means of mon-
itoring seizure activity, intracerebral cannulation for drug delivery
or sampling, as well as optical ﬁbres for optogenetic illumination,
which can be coupled with recording and stimulation (“optrodes”)
can be used to monitor and inﬂuence seizure activity. The consid-
erations described below apply to these techniques.
The main welfare issues to be taken into consideration for
chronic electrophysiological recording are the experimental setup
(tethered systems or radiotelemetry), electrode properties (e.g.
physical dimensions, location and logistics of device), surgical
implantation of electrodes (e.g. infection, post-operative recovery)
and maintenance of chronic electrodes (e.g. freedom of movement,
cage size). A detailed account of the technology is beyond the scope
of the paper but the reader is referred to Weiergraber et al. (2005).
Experimental setup: Data transmission can be achieved using
either umbilical cables (tethers) or radiotelemetry. Tethered sys-
tems constrain movement. Torque on the headmount can be
minimised by the use of slip rings (swivel commutators), reducing
the risk of injury to the animal. The combined weight of the head-
mount, plug and cable can be managed by carefully adjusting the
4 NC3Rs funded CRACK IT challenge ‘Rodent Little Brother’ https://www.crackit.
org.uk/challenge-7-rodent-little-brother.
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improving study outcomes.
To understand current practices, evidence was gathered from
the survey and literature search. The survey asked researchers how
they avoid and minimise adverse effects (Fig. 4). The most common
Group housing
Refine welfar e monitoring  protocol
Administer  periph eral antago nist
Additio nal  warmth
Extra nesting material
Provide analgesia
Minimise duration of study
Limit intensity of seizures
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ength of the tethering cable, or by use of a counterweight or spring
o adjust the cable to follow movements of the head. Careful atten-
ion to both vertical and rotational forces can allow continuous
ecording for weeks (Doheny et al., 2002).
Radiotelemetry avoids tethering wires and therefore allows ani-
als to move freely, which has beneﬁts for behavioural studies,
nimal welfare and can simplify longer-term recording (Bastlund
t al., 2004; Weiergraber et al., 2005; Williams et al., 2006). The
evelopment of such devices should include evaluation of their
mpact on the viability of adjacent tissues. Battery life is a key factor,
articularly for studies on seizure frequency or on disease progres-
ion. Recording from early post-natal animals is more challenging
Zayachkivsky et al., 2013).
Device dimensions and locations: The physical size and weight
f devices can impact on the welfare of the animal. Devices should
e as light as possible and positioned appropriately to allow the ani-
al  free movement to perform its normal behaviours, particularly
o eat, drink and groom (Morton et al., 2003). It is difﬁcult to deﬁne
n exact weight limit. The experience of the Working Group is that
evices of 5–10% of bodyweight appear to be tolerated, although
here are no published data to support this.
Devices can be mounted in the locations listed. In general,
mplanted devices should be positioned away from the incision (i.e.
ot directly under the sutures).
 Head mounted—This is most common with tethered systems
and some radiotelemetry systems.
 Subcutaneous—If radiotelemetry devices are small enough they
can be implanted subcutaneously with wires tunnelled to the
recording sites. Their size, weight and location should not place
excessive strain on the skin or musculoskeletal system. Differ-
ences in skin properties (e.g. between rat and mouse, different
parts of the body) can determine whether devices will remain
in the pockets created for them, or whether they need tethering,
for example with a permanent suture.
 Intraperitoneal—Some devices are too big to mount subcuta-
neously and are implanted inside the abdomen. Care is needed
on the locations of devices and the paths of wires to the recor-
ding sites to avoid restricting natural movements and to avoid
mechanical damage to adjacent tissues.
 Harnesses—Some systems use species-speciﬁc harnesses or sad-
dles to carry external batteries or even the entire device (Ewing
et al., 2013). They should be appropriate to the age/size/species of
the experimental animal under study and permit free movement
with frequent checks made for evidence of rubbing or discom-
fort.
Surgical implantation of electrodes: In almost all cases elec-
rophysiological recording requires preparatory surgery to implant
r attach electrodes, connectors, telemeters, cannulae and other
evices. Electrodes can be implanted into brain structures using
tereotaxic surgery, or onto the cortical surface using either a skull-
crew electrode or a wire cemented into a burr hole. Large numbers
f electrodes can be incorporated into ultrathin and ﬂexible elec-
rode arrays (Wu et al., 2008; Viventi et al., 2010; Park et al.,
014).
Good surgical practice, with proper attention to antibiotic
rophylaxis, full aseptic technique (see video tutorials on the
C3Rs-funded Procedures With Care website4), pain management,
aintenance of body temperature, replenishment of ﬂuids lost
nder anaesthesia and effective post-operative care are required
see Section 3.4) (Fornari et al., 2012). In some cases surgery can
e extensive, requiring careful planning and execution of both the
peration and subsequent post-operative care.
Whatever the electrode assembly, it needs to be securely
nchored in place. Loss of the head stage was reported in the surveynce Methods 260 (2016) 2–25 9
as a deﬁned humane endpoint (see Section 3.5). Typically electrodes
will be ﬁxed to the skull using cement (e.g. dental acrylic or glass
ionomer) and anchoring skull screws. In some cases skull screws
are not feasible (e.g. in the thin skulls of neonatal rats), in which
case, careful matching of the shape of the device to the slight cur-
vature of the skull allows the use of cyanoacrylate glues to anchor
radiotelemetry devices (Zayachkivsky et al., 2013).
Animals with head-mounted devices may require additional
housing space and it may be prudent to block access to low food
hoppers, or to avoid wire lids with gaps that can trap projections
from the head-mount. Choices of housing should also consider the
risk of damage to head-mounted items (see Section 3.8 Enrich-
ment). The latest individually ventilated cage (IVC) systems include
double height cages from which the shelf can be removed to
minimise the risk of head implants being caught in the cage or
lid.
Recommendations:
8. The experimental setup should be maximally effective in
delivering the research objectives while prioritising animal
welfare and minimising interference with behaviour, espe-
cially in behavioural studies where the instrumentation for
seizure recording may  impede movement and signiﬁcantly
alter behaviour (Grade D).
9. Wherever possible, radiotelemetry should be used in pref-
erence to tethered systems for chronic electrophysiological
recordings (Grade D).
10. Radiotelemetry devices should be as light as possible, con-
sistent with the scientiﬁc objectives. Consideration should be
given to the physiological conformation of the device and its
potential impact on posture and natural behaviours (e.g. eat-
ing, drinking, grooming and rearing) (Grade C; Morton et al.,
2003; Hawkins et al., 2004, Level III).
11. Good surgical practice and aseptic technique should be used,
with pain management, maintenance of body temperature,
replenishment of ﬂuids lost under anaesthesia and effective
post-operative care and consideration of antibiotic prophylaxis
(Grade D) (see recommendation 15).
3.4. Perioperative care
Several models of epilepsy require surgical procedures to be
undertaken for intracranial electrode implantation and stimulation
(see Section 3.3) and/or stereotaxic injection of seizure-inducing
compounds (Bouilleret et al., 1999; Lévesque and Avoli, 2013). The
care provided before, during and after surgical procedures (peri-
operative care) is critical for minimising pain and discomfort, andNumber of  reports  from survey
Fig. 4. Reﬁnement of adverse effects during induction and/or maintenance of exper-
imental epilepsy. Steps taken to control and reﬁne adverse effects in response to the
question: “How do you control and reﬁne adverse effects?”.
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ontrol measure was modiﬁcation of the food source provided to
nimals to encourage eating and prevent weight loss, for exam-
le softened standard food pellets, gels and treats, which are often
laced on the cage ﬂoor. In addition to modiﬁcations detailed in
ig. 4, researchers also reported administration of subcutaneous
uids following surgery, application of topical and systemic antibi-
tics to prevent infection, extra care when handling seizure-prone
nimals, and the use of skilled and knowledgeable animal care
taff, with good communication between them, veterinarians, and
esearchers.
Animals should be given time to recover from surgery before
 study commences and provided with necessary resources, for
xample, heating blanket or a temperature-controlled warm cab-
net (avoid the use of heat lamps) to prevent hypothermia until
here is evidence of recovery (McIntyre, 2005; Zhao and Holmes,
005; Graber and Prince, 2005).
Analgesia and anaesthetics: Question 5a of the survey asked
esearchers: “What adverse effects do you observe at induction
nd/or during maintenance of experimental epilepsy?” Pain-
elated behaviour was reported in 3/44 (7%) of responses and
ll such cases were associated with chemically-induced epilepsy
uring the induction process. No pain-related behaviours were
eported to be observed during maintenance of epileptic animals.
se of analgesia was reported in 18/51 (35%) responses to question
b “How do you control and reﬁne adverse effects?”; however this
ay  reﬂect under-reporting of standard practice.
Pain during seizures is a rare phenomenon in people with
pilepsy (Young and Blume, 1983) and it is thought to have a
imilarly low incidence in animal models of seizures. Postictal noci-
eptive thresholds have been assessed in experimentally-induced
pileptic seizures in animals using thermal nociceptive tests (tail
ick, plantar, hot plate) showing a postictal anti-nociceptive effect
bserved for 30–120 min  after seizures (Caldecott-Hazard and
iebeskind, 1982; Caldecott-Hazard et al., 1982; Coimbra et al.,
001; Freitas et al., 2005; Maresˇ and Rokyta, 2009). Longer-term
nti-nociceptive effects have not been deﬁned. Although it appears
ain associated with seizures is minimal and infrequent, there is, as
or all surgical procedures, the potential for animals to experience
ain. Protocols for identifying and alleviating pain around this time
re therefore required.
To estimate current practice in analgesic administration in ani-
al  models of epilepsy undergoing surgical procedures, a small
iterature review was carried out. Peer-reviewed scientiﬁc papers
eporting kainic acid-induced seizures published between 2012
nd 2014 were included in the analysis. A total of 20 papers were
creened for inclusion eligibility (i.e. if the paper described surgical
rocedures); eight papers were excluded because no surgical pro-
edures were involved. Of the 12 papers included in the analysis
Guo and Kuang, 1993; Inostroza et al., 2012; Bernard et al., 2013;
hung et al., 2013; Xu et al., 2013; Dugladze et al., 2013; Harhausen
t al., 2013; Huang and van Luijtelaar, 2013; Jimenez-Pacheco et al.,
013; Li et al., 2013; Qiao et al., 2013; Simeone et al., 2014), 11/12
92%) reported the use of anaesthetics, but only 3/12 (25%) reported
he use of analgesics. The low level of reporting of analgesia is con-
istent with previous reports in rodents undergoing experimental
urgical procedures (Richardson and Flecknell, 2005; Stokes et al.,
009)); however this may  reﬂect under-reporting. Until the ARRIVE
uidelines5 are routinely and fully implemented when reporting
nimal studies, it will remain difﬁcult to ascertain whether pain is
eing managed appropriately.
5 Led by the NC3Rs, the ARRIVE guidelines (www.nc3rs.org.uk/ARRIVE) were
eveloped to improve the reporting of animal research, maximise the information
ublished and minimise unnecessary animal use. (Kilkenny et al., 2010).nce Methods 260 (2016) 2–25
Anaesthesia and analgesia should be used to alleviate pain asso-
ciated with invasive procedures such as stereotaxic delivery of
convulsants and electrode implantation. In other surgical contexts
analgesia has been shown to aid recovery (Hayes et al., 2000;
Shavit et al., 2005). The anaesthetic and analgesic formulation, dose
and route of administration should follow advice from the veteri-
narian, and should be reported in published papers. Anaesthetic
agents should be chosen carefully due to their potential effects on
the physiology of the animal (Tremoleda et al., 2012). For exam-
ple, pilocarpine-induced SE rats show an enhanced response to
general anaesthesia (pentobarbital, halothane and propofol), pro-
longed loss of tail-pinch response and loss of righting reﬂex. In
contrast, the amygdala kindling model does not show enhanced
response to general anaesthesia (Long et al., 2009).
There are indications that certain analgesic drugs (e.g. neu-
roleptics and opioids) have an effect on seizure susceptibility and
expression (Czuczwar and Frey, 1986; Hashem and Frey, 1988).
Pharmacokinetic and pharmacodynamic factors need to be con-
sidered with co-administration of drugs. If this is a problem in
the speciﬁc model being produced, then alternative agents such as
NSAIDs (see Glossary) combined with local anaesthetic block using
a combination of lidocaine and bupivacaine can be considered. Care
must be taken with local anaesthetics as leakage onto the cortex can
cause seizures. The use of analgesics may  be required under legisla-
tion in some countries unless there is robust scientiﬁc justiﬁcation.
Withholding of analgesia following an invasive procedure must be
justiﬁed to the AWERB/IACUC (see Glossary).
The Mouse Grimace Scale (Langford et al., 2010; Leach et al.,
2012) and Rat Grimace Scale (Sotocinal et al., 2011; Oliver et al.,
2014) have been shown to be rapid, reliable and effective methods
for assessing post-operative pain. An additional question about use
of grimace scales “Do you use the Mouse Grimace Scale (MGS) or the
Rat Grimace Scale (RGS) to assess pain?” was  added to the survey.
Only four respondents (13%) used the grimace scales to assess pain
in mice and rats.
Infection: Inﬂammation due to infection can interfere with
seizure susceptibility and infections have been shown to cause
higher seizure susceptibility in audiogenic and electroshock-
induced seizures (Flandera et al., 1973). Prenatal immune
challenges can also cause an increase in seizure susceptibility (Yin
et al., 2013). In the survey, only two  survey respondents reported
post-operative infection; one as a criterion for the humane end-
point and the other as a complication of surgery, which was
avoided by using topical antibiotic application. Infections should be
avoided by using best practices, including aseptic technique dur-
ing surgical procedures. However, maintaining strict asepsis during
complex implant procedures can be challenging, and as an adjunct
to this, prophylactic antibiotic treatment should be given if appro-
priate on the advice of the veterinarian. The choice of antibiotics
requires careful consideration; evidence suggests the tetracycline-
class antibiotics (e.g. minocycline, doxycycline and tetracycline)
have anti-apoptotic and anti-inﬂammatory effects (Abraham et al.,
2012; Wang et al., 2012).
Food and ﬂuids: Following induction, the feeding behaviour
of animals may  become disrupted. For example, animals injected
with tetanus toxin display intermittent attacks of ‘paroxysmal eat-
ing’ lasting a minute or two, where animals consume their food
pellets with excessive vigour (Mellanby et al., 1999). Modiﬁcation
of food source was  the most frequently reported method to min-
imise adverse effects (weight loss) mentioned in the survey. Several
studies have reported using modiﬁed food, including enhanced
dietary glucose to accelerate weight gain following SE (Jedrzejko
and Persinger, 2001). Hand-feeding animals with fruit juices mixed
with sweetened milk or mashed food pellets can also be bene-
ﬁcial for animals in a poor condition following seizure induction
(McIntyre; Persinger et al., 1988).
roscience Methods 260 (2016) 2–25 11
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Recommendations:
2. Animals should be allowed sufﬁcient time to recover follow-
ing surgical procedures using anaesthesia, before subsequent
recordings/measurements are taken (Grade A; Culley et al.,
2004, Level I+).
3. Steps should be taken to identify, assess and alleviate pain fol-
lowing procedures requiring surgery. Appropriate pain relief
should be provided and reported in publications. Choice of anal-
gesic should be made with care based on veterinary advice and
taking into account evidence of potential interference with the
science (Grade C; Tremoleda et al., 2012, Level III).
4. Topical antibiotics should be used for simple surgical pro-
cedures and prophylactic antibiotics used for implantation
procedures if appropriate, based on veterinary advice (Grade
D).
5. A modiﬁed food source should be provided to encourage eat-
ing and prevent weight loss following surgery and/or seizure
induction (Grade A; Jedrzejko and Persinger, 2001, Level I). This
should be introduced prior to surgery to ensure familiarisation
and consumption. Food and drink should be accessible from the
ﬂoor of the cage (Grade D).
.5. Welfare assessment
The creation of chronic disease conditions, including rodent
odels of epilepsy, requires continuous welfare assessment. The
everity and frequency of the adverse effects will depend upon
he model of epilepsy. Genetic models may  show early failure to
hrive and excess neonatal and juvenile mortality. Other models
f epileptogenesis in previously normal animals may  also present
elfare issues unique to the induction method (e.g. electrical stim-
lation or chemical treatments). Once the epileptic state has been
roduced, on-going adverse effects related to the seizure activity
ust be taken into account. In addition to providing an immediate
ssessment of the animal’s state of health and welfare, the infor-
ation gained from welfare assessments enables compliance with
he legal requirements in many countries for prospective severity
lassiﬁcation of the experimental procedures and subsequent ret-
ospective assessment of severity experienced by the animals (see
nnex VIII of Directive 2010/63/EU). The severity classiﬁcation can
e assigned according to clinical signs observed during the assess-
ent (Baumans et al., 1994). This can then be used to determine the
ppropriate action regarding the continuation of a study with due
llowance for safeguarding animal welfare. The assessment should,
henever possible, use data from adverse effects observed in the
nimal model, rather than by simple extrapolation from man.
The survey showed adverse effects observed at induction
nclude high mortality, weight loss and, in some cases, pain-related
ehaviour. During the maintenance phase the most commonly
eported adverse effects were behavioural abnormalities, such as
ggression and hyper-reactivity (Fig. 5). Management of aggres-
ion can result in animals being singly-housed, further impacting
n their welfare (see Section 3.7 Social housing). Evidence from
he literature search shows that the number of seizures and
eizure-induced neuronal damage is correlated with the severity of
ggression in animal models of epilepsy (Desjardins and Persinger,
995; Persinger, 1996; Huang et al., 2012). Some methods to induce
eizures, such as kindling, can result in long-lasting changes in
motional behaviour (Franke and Kittner, 2001), which have been
hown to be defensive in nature (Kalynchuk et al., 1999). However,
ome comorbidities associated with clinical epilepsy (e.g. aggres-
ion) are an integral part of the disease and may  be the object of
he research.
Animal welfare assessments must be conducted to assess the
tate of wellbeing and health of each individual animal. Wheretion: “What adverse effects do you observe at induction and/or during maintenance
of the experimental epilepsy?”.
experimental procedures unavoidably impact on the health of the
animal, which includes many disease models, appropriate welfare
assessments will enable the impact of the procedures to be recog-
nised and action taken to minimise harm by intervention/treatment
and the application of humane endpoints (see Section 3.7).
Effective and regular monitoring of welfare is best facilitated
by the use of score sheets (Jones et al., 1999; Morton, 1999, 2000;
Hawkins, 2014). The survey showed 21 respondents (38% of the
total) reported using a scoring system. Using a formalised scoring
system has the advantage of encouraging a systematic, structured
examination of the animal, and helps ensure a consistent evaluation
at different time points, and by different assessors. Scores sheets
also provide a useful basis for communication between researchers
and animal care staff. How to best tailor the most appropriate sco-
ring system for each establishment, species, project and group of
personnel has been reviewed in detail by Hawkins et al. (2011).
Examination of the animal’s physical appearance and behaviour
is essential for the conduct of welfare assessment. Routine obser-
vations should be performed on a daily basis, and this is a legal
requirement under some jurisdictions, although speciﬁc reports are
typically only made if there is concern over the health of the ani-
mal. A more detailed welfare assessment scoring system should
be considered, particularly if new models are being introduced,
or if a particular model is known to present signiﬁcant comor-
bidities. Criteria used for scoring systems that were described by
respondents in the survey included body weight, fur condition,
piloerection, colour of skin, aggressive behaviour, social interac-
tions, ocular keratitis, ataxia,  tremor, ptosis, straub tail,  righting
reﬂex, mydriasis, catalepsy and mortality rate (see Glossary). In
addition, Table 4 provides a list of general welfare assessment crite-
ria for laboratory rodents. Assessments should be made both by
observation of the animal in an undisturbed state, and then by
more detailed inspection involving, if necessary, removal from its
cage. Care is needed, however, where handling may  provoke hyper-
reactivity and compromise, rather than promote animal well-being.
Due to the speciﬁc nature of animal models of epilepsy and
their associated adverse effects, a number of scoring systems have
been developed to capture the seizure type observed. The Racine
Scale (Racine, 1972) was originally developed to classify seizures
induced by electrical stimulation to the hippocampus or amygdala
in rodents. The modiﬁed Racine scale was introduced for PTZ chem-
ical induction (Lüttjohann et al., 2009) and describes a wider range
of motor seizures, possibly due to the convulsant reaching more
parts of the brain than the focal stimulation of amygdala kindling.
It is important to realise that these scales are not necessarily gener-
alisable to other seizure models and immature animals. Proposals
have been made to quantify animal suffering based on seizure sco-
ring (Wolfensohn et al., 2013) but the Working Group considers
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Table 4
Welfare assessment criteria. Examination of an animal’s physical appearance and behaviour is essential for the conduct of the welfare assessment. Table
adapted from AHWLA (Assessing the Health and Welfare of Laboratory Animals) www.ahwla.org.uk and based upon experience from the Working Group.
Positive welfare indicators (grey) and negative welfare indicators (white) are categorised into three distinct areas: the cage environment, animal behaviour
and  the physical appearance of the animal.
Catego ry Indicators  
The cage 
environ ment 
Evidence of eating and drinking 
Evid ence of fresh faeces and urine 
Evid ence of ne st buildin g and  use / a good quality nest  (mice)  
Any blo od staini ng of the c age sides  or bedd ing 
Animal 
behavio ur 
Alert  to extern al st imuli  
Interested  in surround ings (e .g.  use of enrichment it ems)  
Normal in terac tions  with handlers (e .g. no t overly aggressive or overly passi ve) 
Normal in terac tions  with other  animals  (e.g. no increa se in agg ression  or an xie ty beha vio ur, such mark ed escap e 
respon ses  or h idin g) 
Isola ted or withdra wn fro m other an imals in  the social  gro up 
Abnormal po sture (e.g. hun che d posture , tilted head ) 
Abnormal movemen ts (e. g. ab normal  gait , uncoo rdinated movement, lack  of movement in  the c age or on the ben ch) 
Physical 
appeara nce 
of the 
animal 
 
Good body conditi on (i.e. not overco nditio ned or underco nditio ned  as  defined i n Ullman-Culleré & Folt z 1999 
Appropriate bod y weig ht (i.e. wit hin  normal  range for a ge-matc hed  con trols; no significa nt weight loss  or incre ase) 
Mucou s membrane s pink  and moist  
Eyes clea r and bright; fre e from disc harge or pro phyrin staini ng (rat) indica tive of stress or dise ase; not sunken, dull or 
closed/semi-clos ed 
Nose fre e from disc harge 
Mou th (incl udin g teeth and  tongue ) free  from injur y or abno rmaliti es  (e.g. malocclusi on/overgrown tee th, salivati on) 
Tail and  anal  genit al  area  free from injur y and disch arge/s oiling  
Normal skin  an d limbs (e. g. free from ph ysical i njur y, lack  of skin ten ting  = deh ydration) 
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ePoor coat conditi on (e.g. un kempt due to lack of
Abnormal facial  expre ssio ns,  indica tive of pain (
mou se (Lan gford  et al. 2010) grimace scales
his to be of limited value due to poor association of seizure score
ith animal suffering.
Recommendations:
6. Each animal model of epilepsy should be assessed and an appro-
priate welfare score sheet validated by both animal care staff
and the principal investigator. The score sheet should deﬁne
when action should be taken to minimise pain, suffering and/or
distress by intervention/treatment and application of humane
endpoints. Such scoring systems should incorporate both moni-
toring of actual model induction and monitoring of the resulting
epileptic state (Grade D).
7. Animal welfare assessments should be conducted at a fre-
quency appropriate to the state of well-being and health of the
individual animal; at least on a daily basis and multiple times
per day in the immediate post-operative recovery period or
following speciﬁc interventions (Grade D).
.6. Humane endpoints
Humane endpoints can be deﬁned as a set of predetermined
hysiological and/or behavioural signs that deﬁne the point at
hich an animal will be removed from an experimental study (e.g.
y humane killing) before it experiences unacceptable harm whilst
till meeting the experimental objectives. The implementation of
umane endpoints is a major means of reﬁnement (Morton, 1999;
endriksen et al., 2011; Ashall, 2014). Identiﬁcation of humane
ndpoints needs to take into account clinical aspects of the dis-
ase being modelled, which arguably can be harmful while being
egitimate subjects for study; in such cases, care needs to be taken
o balance harms and potential beneﬁts.Clearly deﬁned scientiﬁc objectives are pivotal to help deter-
ine the earliest experimental and humane endpoints. The most
ffective biological indicators that denote success or failure of an
xperiment and which precede any unjustiﬁable suffering of anmin g, gre asy, faecal or urine stain ed, piloe rection, hair loss)   
rimace score of 1 or 2 usin g the  rat  (Sotoci nal  et al.  2011 ) and 
animal, should be obtained prior to the start of the experiment and
reviewed regularly by a team of animal care staff, the scientists and
the veterinarian (Ashall, 2014; Hawkins, 2014). Successful imple-
mentation of humane endpoints relies on training and teamwork
(Hau, 1999; Hawkins et al., 2011). To ensure animal suffering is
kept to an absolute minimum, the predetermined biological indi-
cators of suffering and poor welfare need to be detected as quickly
as possible and acted up on efﬁciently, for example by providing
veterinary care such as pain relief or, if necessary, euthanasia of
the affected animal.
Few published epilepsy studies address the issue of humane
endpoints (Lüttjohann et al., 2009). Therefore the survey was used
to assess when and how humane endpoints are used in animal
models of epilepsy. Humane endpoints were used by 39/44 (67%)
respondents to question 6 “Do you use a deﬁned humane end-
point?”; with the most common humane endpoint criteria being
signiﬁcant body weight loss (ranging from 10% to 25% weight loss
from pre-induction starting weight), signs of distress (including
porphyria staining, poor grooming, difﬁculty breathing), opening
of wounds or loss of an implant, wound infection, and prolonged
repetitive seizures. Following a very prolonged seizure (SE) or post-
operatively (pain), animals can have difﬁculties drinking or eating,
which can result in a signiﬁcant decrease in body weight due to
dehydration or reduced food intake.
The results of the survey reﬂect that the single most objec-
tive clinical sign is change in body weight (Van Vlissingen et al.,
1999). Body weight is easy to measure and record but is a relatively
non-speciﬁc welfare indicator. Both an abnormal increase and a
substantial decrease in body weight can be associated with serious
distress and suffering. The rate of change, as well as the absolute
change, can be of importance.In epilepsy models sudden increases in body weights can be
observed, associated with unrelated illnesses such as the devel-
opment of neoplasms and ﬂuid retention. Seizures can result in
body ﬂuid loss and this can produce short-term changes in weight.
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areful monitoring of body weight therefore needs to be carried out
egularly (see Section 3.5) and diet amended as necessary. If an ani-
al  does not eat or drink normally and as a result has a signiﬁcant
ody weight loss, euthanasia should be considered.
Body weight measurements should not only be compared to the
revious measurements, but also plotted in a chart and compared
o the normal growth curve for that species and strain. This will
nable assessment of whether the animals are growing normally;
ondition scoring can also be used for this purpose (Ullman-Culleré
nd Foltz, 1999; Hickman and Swan, 2010). For example, reduc-
ion in weight gain or an absolute loss in body weight can be
sed to determine a humane endpoint (Jones et al., 1999). Use of
eight as the sole criterion for application of a humane endpoint
s often inappropriate (Chapman et al., 2013); in addition to body
eight loss, other “signs of distress” should be identiﬁed, for exam-
le; appearance (coat condition, posture and mobility/gait), clinical
igns (respiration, salivation, tremors, prostration), unprovoked
ehaviour (socialisation, vocalisation) and response to stimulus
provoked behaviour) (Jones et al., 1999).
Deﬁned endpoints need to be tailored speciﬁcally to the epilepsy
odel used. The type, duration, intensity and frequency of seizures,
ecovery time and the level of suffering following the initiation of
 seizure (if not spontaneous recurrent seizures) considered to be
cceptable will differ with each experimental model and needs to
e deﬁned. For example, if SE cannot be stopped by pharmaco-
ogical intervention within the deﬁned time, the animal should be
uthanised. If SE is not the expected outcome of the model, it should
e avoided and controlled if it occurs unexpectedly.
Recommendations:
8. A tailored approach should be adopted to assess, deﬁne and
implement humane endpoints for each experiment in order to
minimise harms, whilst allowing achievement of the scientiﬁc
objectives (Grade C; Morton, 1999, Level III). This should take
into consideration the current legal framework, scientiﬁc, justi-
ﬁable and unpredicted endpoints (see Glossary) and the results
of welfare assessments.
.7. Social housing
Social interactions are important contributors to the welfare
f rodents, provided that the group composition is appropriate
or the species, age, sex and strain. Social housing is the rec-
mmended default housing conﬁguration under legislation on
rotection of animals used in science (European Union, 2010;
ational Research Council, 2011; Home Ofﬁce, 2014). Individual
ousing has been shown to be stressful for rodents, giving rise to
ehavioural and physiological abnormalities (Hatch et al., 1963;
rain, 1975; Haseman et al., 1994; Hurst et al., 1997; Võikar et al.,
005; Meijer et al., 2006; Kalliokoski et al., 2014), and is there-
ore recognised as a harm and regulated under some jurisdictions.
ousing of single-sex groups of male and female rats does not
Non-instrumented
Instrum ented
0 10 20 30 40 
% of  re 
Fig. 6. Social housing of instrumented and non-instrumented animals in responnce Methods 260 (2016) 2–25 13
usually pose problems. Socially housed male mice, however, may
show territorial behaviour, aggression and ﬁghting, depending on
strain, previous experience and cage enrichment (Van Loo et al.,
2001). Nonetheless, there is evidence that subordinate male mice
prefer company to being housed individually, even if their compan-
ion is dominant (Van Loo et al., 2001). Provision of visual barriers
and refuges that allow animals to withdraw out of sight when a
threat occurs can reduce aggression.
The issue of group or single housing for rodents used in epilepsy
studies is complex. Whilst group housing should be best practice,
the removal of individual animals for surgery or behavioural test-
ing can result in the disruption of an established social hierarchy
(Ferrari et al., 1998; Bartolomucci et al., 2001, 2004; Arndt et al.,
2009), whilst the appearance of disturbed behaviour (aggressive-
ness or passivity) in experimental animals (e.g. animals displaying
overt seizures (Mellanby et al., 1981) or that are instrumented) may
provoke hostile responses from cage-mates. Companion rats have
been seen to bite rats that are experiencing seizures and may  cause
injury, or they may  bite exposed devices including head-mounted
guide cannulae, electrophysiological connections and telemeters;
in either of these cases, the animals should be separated. Early after
major surgery a companion may  eat appealing foods faster than the
recovering rat and delay restoration of weight. On rare occasions
apparently neutral behavioural contact between rats has triggered
seizures, so that removing the companion may be beneﬁcial for
the epileptic rat. The tendency for epileptic rats to be submissive
may  affect the social hierarchy in group housing which could create
confounds for some kinds of experiments (Castelhano et al., 2013),
particularly for those investigating behavioural comorbidities.
Several studies support the hypothesis that social housing accel-
erates post-surgical recovery in rodent disease models (Baran et al.,
2010; Jirkof, 2015). The survey asked how animals were housed
during an experiment (after induction) and the results showed that
instrumented animals were more likely to be singly housed (36/49,
73% of total) compared to non-instrumented animals (16/49, 33% of
total) (Fig. 6). Rodents are often housed individually after surgical
procedures because they may  disturb each other’s incisions, but this
is a rare occurrence and may  be addressed by use of subcuticular
sutures. The experience of some members of the Working Group
is that a familiar companion animal helps accelerate recovery of
animals that have undergone prolonged and/or complex surgery,
but that the companion animal may  need to be removed if ﬁghting
occurs. Group housing needs careful monitoring, ideally with video
recording, to detect adverse effects that may be detrimental to the
welfare of the epileptic animal or to the reliability of the experi-
mental results. The possibility exists to divide cages with a grid-like
barrier that allows odours and some physical contact whilst reduc-
ing the risk of serious injury and allowing retreat to safety (Van Loo
et al., 2007; Boggiano et al., 2008). Whilst this seems like a suitable
compromise, space issues arise if larger rodents such as rats are
conﬁned to one half of a standard cage (Boggiano et al., 2008) and
increased levels of stress were reported in mice separated by a grid
50 60 70 80 90 100
ports from  sur vey 
Singly ho used Grou p/pair  housed
se to the question: “How are the animals housed during an experiment?”.
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eading the authors to conclude that even individual housing may
e more suitable than separation by a grid (Van Loo et al., 2007).
In summary, the balance of pros and cons in social housing
s very delicate. The incidence of complications of group hous-
ng varies greatly between models, and possibly between strains
f experimental animals. A companion animal allows for natural
ocial interactions beneﬁcial for welfare and seems to accelerate
ecovery from more difﬁcult surgeries, but it is a delicate balance.
his was reﬂected in the survey, which showed respondents housed
nimals individually (23/56, 41% of total responses) or in groups
10/56, 18% of total responses) as reﬁnement measures (Fig. 4). We
onclude that group housing is desirable in some, but not all, work
n experimental epilepsy, and that each case should be carefully
valuated, weighing the welfare beneﬁts and costs against single
ousing. When individual housing is inevitable due to excessive
ggressive behaviour, the presence of enrichment objects such as
esting material can mitigate some of the negative consequences
f social isolation (Belz et al., 2003; Van Loo et al., 2004).
Recommendations:
9. Mice and rats should be socially housed unless there are com-
pelling scientiﬁc or animal health reasons for single housing.
Each case should be carefully evaluated; weighing the welfare
beneﬁts and costs (Grade A; Võikar et al., 2005; Kalliokoski et al.,
2014, Level I).
0. Animals should be paired or grouped prior to surgery to
increase the social bond, thereby reducing the risk of adverse
behaviour towards the operated or instrumented animal(s)
(Grade D).
1. Socially housed animals should be monitored to identify signs
of aggressive behaviour and the consumption of supporting
supplementary food intended for the experimental animal
(Grade A; Mellanby et al., 1981, Level I).
.8. Environmental enrichment
Most rodents used in epilepsy studies spend the majority of
heir time in their cages, so reﬁnement of housing and husbandry
s a key issue. Providing an environment which meets the animals’
pecies-speciﬁc behavioural and physiological needs is important
or their wellbeing (Olsson and Dahlborn, 2002; Baumans, 2005;
ubrecht and Kirkwood, 2010). Despite many generations of breed-
ng in captivity, laboratory rodents are still motivated to perform
ehaviours seen in their wild counterparts (Berdoy, 2003). Barren,
estrictive and socially-deprived housing conditions can interfere
ith brain development and cause abnormal behaviours, such as
tereotypies and barbering. Animals from reﬁned housing con-
itions are expected to be physiologically and psychologically
ore stable and might therefore be considered superior animal
odels, ensuring more generalisable results (Poole, 1997; Martin
t al., 2010; Kulesskaya et al., 2011). Structuring the cage with
esting material, nest boxes, tubes, partitions and chew blocks
llows for the performance of natural behaviours, such as nest
uilding, hiding, exploration, foraging, gnawing and resting and
rovides the animals with an element of choice, complexity and
ontrol (Sherwin and Nicol, 1997; Manser et al., 1998b; Latham
nd Mason, 2004; Baumans, 2010). Environmental enrichments can
lso provide useful indicators for severity assessments, as animals
ith poor welfare are less likely to utilise enrichment objects and to
arry out normal behaviours such as nest building (Hawkins et al.,
011). Preference tests and consumer demand studies have been
sed to determine the strength of motivation for speciﬁc resources.
or example, Manser et al. (1996) showed that rats were moti-
ated to lift a door weighing 83% of their bodyweight to rest on
 solid ﬂoor rather than a grid ﬂoor; Collier et al. (1990) showed
hat rats will continue to press a bar to open a door to gain accessnce Methods 260 (2016) 2–25
to a nest box even when required to do so 20 times per entry;
rats prefer chewable over non-chewable objects and show a clear
preference for dark nest boxes (Manser et al., 1998a). Alternatives
to standard housing systems that better cater for the behavioural
needs of rodents are commercially available (e.g. elevated cage tops
and multi-level cages that allow exploration, climbing and rearing).
The concept that environmental enrichment improves cogni-
tion and well-being in rodents has long been established and
a wealth of literature demonstrates that environmental enrich-
ment alters synaptic plasticity, brain (and neuronal) morphology,
neurogenesis, neurochemistry and gene expression (Lewis, 2004).
Environmental enrichment has been shown to modify pathology in
rodent models of neurodegenerative disease (Hannan, 2013) and
the inﬂuence of environmental enrichment speciﬁcally in the con-
text of epilepsy and epileptogenesis has recently been reviewed
(Kotloski and Sutula, 2014). Some salient points are highlighted
below.
Many studies have demonstrated that environmental enrich-
ment has a dramatic effect on seizures and their comorbidities,
but the effects of environmental enrichment are model-dependent.
In the kainic acid model of limbic SE, environmental enrichment
prior to the SE is neuroprotective, increases neurogenesis, and
increases seizure threshold (Young et al., 1999). Similarly, in a
genetic model of temporal lobe epilepsy secondary to a missense
mutation of the sodium channel NaV1.2 gene (Scn2a), environmen-
tal enrichment from birth greatly reduced spontaneous seizures
and neuronal damage (Manno et al., 2011), whilst mice with a
mutation in the presynaptic protein bassoon experienced shorter
tonic–clonic seizures and a preservation of synaptic transmission
and plasticity (long-term potentiation, paired-pulse facilitation),
dendritic spine density and apical dendrite length in area CA1
of the hippocampus (Morelli et al., 2014). Environmental enrich-
ment after pilocarpine-induced limbic SE has different effects as
there seems to be no effect on EEG or neuronal damage, but cog-
nitive performance is still enhanced and neurogenesis increases
(Faverjon et al., 2002; Rutten et al., 2002). Environmental enrich-
ment has also been shown to delay epileptogenesis and increase
neurogenesis in rats subjected to kindling (Auvergne et al., 2002).
Also, in a model of atypical absences secondary to injection of the
cholesterol biosynthesis inhibitor AY-9944, environmental enrich-
ment had no effect on seizure activity, although it did reverse the
behavioural phenotype in these mice (Stewart et al., 2012). These
results contrast somewhat with results obtained in generalised
epilepsies. In genetic models of absence seizures, environmental
enrichment increases the length and frequency of runs of spike-
wave discharges, but not the number of animals exhibiting them
(Schridde and van Luijtelaar, 2004).
A potential confounder in all these studies is that environmen-
tal enrichment protocols differ. In some cases, cages contain toys,
running wheel, tunnels and food reward (or edible treats), but in
some studies the objects are regularly changed and there is con-
siderable variation in the number of objects in the cage. As a result
of this variation, one research group has developed a standardised
environmental enrichment using an enriched cage, that contains
a maze, which separates food and water bottle compartments and
which offers the potential for increased exercise, multiple activities,
cognitive stimulation and the opportunity of changing the maze, so
introducing novelty (Fares et al., 2013).
Overall, it appears that the effects of environmental enrich-
ment are complex but seem to lessen the cognitive impact of
prolonged seizures and epilepsy. This has potential disadvantages,
in for example drug screening, where reduced seizure frequency or
intensity may  require additional animals to be used to gain sta-
tistical power, although the effects on seizure threshold appear
to be epilepsy-type dependent. Providing standard enriched cages
(e.g. Fares et al., 2013) may  go some way  to preventing variation
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n experimental results between laboratories, but may  have the
isadvantage of promoting a particular view of what constitutes
ppropriate environmental enrichment. Instead, an appreciation of
aturalistic behaviour and attempts at permitting their display in
he laboratory environment may  provide the enrichment necessary
o observe consistent effects of environmental enrichment, includ-
ng on the survival, weight gain and general welfare of rodents
ollowing SE.
Enriching the environment of experimental rodents has been
hown to reduce the impact of both induced and genetic models of
pilepsy and may  therefore increase the number of animals needed
o achieve statistical power. Despite this, the preference should be
o provide an enriched environment using the minimum number
f animals consistent with the scientiﬁc objective.
Recommendations:
2. Environmental enrichment should be provided to allow ani-
mals to express naturalistic behaviours unless there is a
justiﬁed reason to withhold it (Grade A; Koh et al., 2007, Level
I+).
3. Environmental enrichment should be consistent in the home
cage to reduce variability (Grade A; Fares et al., 2013, Level
I+). Enrichment protocols should be described carefully and
detailed in published manuscripts to allow others to adopt a
similar approach and reduce inter-laboratory variations.
.9. Reporting and data sharing
A signiﬁcant proportion of in vivo research publications fail to
eport key details (e.g. animal characteristics, methods to reduce
ubjective bias and statistical analysis) (Rice et al., 2008; Kilkenny
t al., 2009; Vesterinen et al., 2010). During the process of con-
ucting a literature search for this report, it was difﬁcult to identify
dverse events and opportunities for reﬁnement in epilepsy studies
ue to the lack of reporting in this area. Use of the ARRIVE guide-
ines can help to ensure animal studies in the epilepsy research
eld are reported comprehensively; improving their interpretation
nd replication (to build upon the existing knowledge base) and
nhancing the feasibility of systematic reviews and retrospective
nalysis of the preclinical literature. In addition, the use of more
escriptive, standardised wording for recording adverse effects
hould lead to capture of more accurate and meaningful informa-
ion, allowing improved decision making in respect to the severity
f the adverse effects. The survey asked researchers if they use the
RRIVE guidelines when reporting animal research; 16/60 respon-
ents (27%) used the guidelines, 12/60 respondents (20%) did not,
nd 30/60 (50%) were unaware of the guidelines. Endorsement of
he ARRIVE guidelines by journals publishing animal studies in
pilepsy would help to increase their use.
The survey asked researchers “Do you participate in data
haring? (e.g. Code Analysis Repository & Modelling for e-
euroscience (CARMEN) (http://www.carmen.org.uk/) and the
IH-funded International Epilepsy Electrophysiology Portal)”. Only
/60 respondents (12%) reported doing so. The ILAE/AES Transla-
ional Research Task Force is currently generating common data
lements (CDE) and guidelines for preclinical epilepsy research.
hese will include CDE modules for generation of epilepsy models,
re- and postoperative care, monitoring of seizure susceptibility
nd seizures, behaviour and cognition, video-EEG monitoring in
oung rodents, and imaging (Galanopoulou et al., 2013). These
esources are expected to greatly facilitate harmonisation of
xperimental procedures between laboratories (e.g. in preclinical
harmacological or biomarker studies) and standardisation of the
ollection and recording of experimental details, resulting in more
eliable data comparison and data sharing between laboratories.nce Methods 260 (2016) 2–25 15
Publication bias is a recognised problem in preclinical and clin-
ical research, with potential impacts on scientiﬁc progress using
animal models (Sena et al., 2010). The survey asked researchers
how often they reported negative data; 13/56 respondents (23%)
always reported negative data, 24/56 (43%) sometimes did so, 9/56
(16%) rarely did so, and 10/56 (18%) never did so. Of those who
published negative results, 50% published in peer-reviewed jour-
nals (although this was  reported to be challenging), posters and
oral presentations.
Recommendations:
24. Researchers should report their animal studies in accordance
with the ARRIVE guidelines. Journals publishing epilepsy and
seizure studies should: (a) include the guidelines in their
Instruction to Authors; (b) require authors to submit an ARRIVE
checklist with their manuscripts; and (c) encourage editors to
review the checklist (Grade D).
25. Common Data Elements (CDE) should be prepared and used to
help standardise the collection of data, including those relevant
to animal welfare, and facilitate comparison of results (Grade
D).
26. Researchers should take advantage of opportunities to make all
research studies regardless of their ﬁndings openly available
to reduce publication bias in epilepsy research (Grade A; Sena
et al., 2010, Level I+).
4. Model-speciﬁc welfare considerations
Induction methods include systemic injections (e.g. pilocarpine,
kainic acid), intracerebral injections (e.g. kainic acid, tetanus toxin)
and electrical stimulation (both kindling and self-sustaining SE).
Variations in the details of each induction method can have major
impacts on the frequency, duration and severity of the resulting
seizures. The optimal range for each of these features of the chronic
epilepsies depends on the purpose of the research. At one extreme,
basic research on the process of epileptogenesis may  beneﬁt from a
long latent period and low seizure frequency, although progression
to spontaneous seizures should be conﬁrmed in each experimen-
tal cohort. Translational research on treatment, and basic research
on seizure mechanisms, generally requires more frequent seizures:
designing experiments with the power to detect reductions in
seizure frequency becomes easier when seizures are frequent.
The Working Group has developed a framework (Table 5)
for the identiﬁcation of potential adverse effects associated with
epilepsy models and the available reﬁnement opportunities, based
on the approach taken by a European Commission expert working
group on severity assessment (http://ec.europa.eu/environment/
chemicals/lab animals/pdf/examples.pdf). Many of the adverse
effects observed in animal models of epilepsy are not exclusively
prevalent in epilepsy models; therefore the framework is divided
into (a) generic adverse effects and (b) epilepsy-speciﬁc adverse
effects.
A comprehensive review of all epilepsy models surveyed
(Table 3) is beyond the scope of this report. However, some model-
speciﬁc adverse effects are identiﬁed below with suggestions for
reﬁnement. It is recommended that researchers identify and review
reﬁnement opportunities for each epilepsy model using the frame-
work provided (Table 5).
Recommendations:
27. The reﬁnement opportunities framework (Table 5) should be
developed and used for each project as a tool for predicting,
recognising and ameliorating suffering and assessing sever-
ity in the particular epilepsy model being used (Grade D; EU
Severity Assessment Framework, Level IV).
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Table 5
Model speciﬁc reﬁnements.
(a) Generic adverse effects and reﬁnements
Procedures: What are
the animals subjected
to?
Potential adverse
effects/co-morbidities
Risk Possible reﬁnements to reduce suffering Control measures/Humane endpoints
Transient interference with
the brain (e.g. stereotaxic
injection, lesioning)
Death due to
anaesthesia
Low Informed choice of anaesthetic (seek
veterinary advice)
Trained and competent staff. Provide further
training of staff if deaths exceed deﬁned
minimal levels
Animal in optimum physiological condition
prior to anaesthesia
Close supervision of animals
Maintenance of body temperature
Infection Low with good practice Sterile procedures to minimise risk of
contamination
Administer antibiotics
Animal euthanised if clinical signs of infection
are present and cannot be controlled
Post-surgery pain Low with good practice Perioperative analgesia taking full account of
pharmacokinetics
Monitor for signs of pain
Animal euthanised if clinical signs of pain
cannot be ameliorated
Failure of sutures Low to moderate Clinical scoring system to assess welfare
Skilled surgeon. Provide training for staff if
failures repeat in several animals
To be assessed by veterinarian and repaired
under anaesthesia. Animals will be humanely
euthanised if more than one failure occurs
Dehydration Low with good practice Hydration with ﬂuid replacement via
intraperitoneal, oral or subcutaneous route
Glucose saline injection and moist and/or
appealing food
Monitor weight, body condition and ﬂuid
consumption. Kill animal if it cannot maintain
good hydration after deﬁned period of recovery
Implantation of devices
(e.g. electrodes, telemetry,
cannulae, microdialysis
probes, optogenetics)
Interference with
speciﬁc brain systems
Low Avoid implantations that could interfere with
primary sensory and motor areas unless
justiﬁed by careful balancing of beneﬁts and
harms
Ethical review
Inﬂammatory and
other tissue reactions
to foreign bodies
Low with appropriate
materials
Choose biocompatible materials
Use (histo)pathology to determine whether
reactions are excessive
Kill if inﬂammatory reactions are evident in
the living animal
Interference with
behaviour after
recovery
Low with appropriate
design
Devices to be of size, weight and location to
allow animals to maintain themselves in good
condition and perform natural behaviours (e.g.
eating, grooming, rearing)
Use  of previously
implanted devices
Damage to head stage Low with appropriate
design and housing
Counterbalanced swivel commutator used for
connections in order to minimise trauma
Animals housed in special cages to avoid head
stage being trapped or knocked inside the cage
Use cage enrichment which reduces the
chances of damage to the head stage
Animals to be euthanised immediately if head
stage is lost
Loosening of devices Moderate Take care to attach head-mounted devices with
robust methods (e.g. cement, skull screws)
Assess integrity of device regularly
Consider whether repair is possible. Kill animal
if  not
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Table 5 (continued)
(b) Epilepsy speciﬁc adverse effects and reﬁnements
Procedures: What are the
animals subjected to?
Potential adverse
effects/co-morbidities
Risk Possible reﬁnements to reduce suffering Control measures/Humane endpoints
Intracerebral injection of
epileptogenic agent
Adverse reaction to agent (batch
dependent)
Low Assay new batches of agent if possible. Test new batches of agent on
small numbers of animals and adjust dose to achieve required
frequency and classes of seizures
Animal euthanised immediately if
unacceptable adverse effects develop
Induction by SE Prolonged SE induced by
stimulation or systemic injection/s
of epileptogenic agent
High but can be managed
by appropriate control
measures
Anticonvulsants to be given if self-sustaining SE continues beyond
preset limit (e.g. 3 h)
Individual variation in sensitivity
to systemically injected
epileptogenic agents
Moderate Consider administering agent by repeated small doses until SE starts.
More sensitive animals will require fewer doses and thus will avoid
risk  of overdose (Hellier et al., 1998)
SE  induced by electrical
stimulation
Moderate Stimulation to be stopped if animals display “explosive”
running/jumping behaviour that could result in injury to animal or
head stage
Depressed consciousness after SE High but can be managed
by appropriate care
Maintain body temperature and hydration and nurse animals until
they are walking and drinking
Traumatic brain injury Craniotomy Use of artiﬁcial bone Animal euthanised if signs of increased
intracranial pressure (e.g. somatosensory
hypersensitivity, breathing problems)
Hemiparesis Close supervision of animals
Maintenance of temperature, hydration, feeding
Development of
spontaneous seizures
Loss of weight or general condition Low for most models Regular assessment of animal condition by the care and scientiﬁc
teams using bespoke score sheets
Animals to be fed a mashed diet
Increased stress and anxiety Moderate Provide environmental enrichment to reduce stress (e.g. rodent castle
for  animals with head stages)
Hyper-reactivity/aggression Moderate Avoid startling or surprising the animals (e.g. loud noises or sudden
movements of humans). Ensure the animals are placed in a quiet room
with minimal disturbance
Avoid unnecessary handling of animals (e.g. plan cage changes around
the hypersensitive period upon seizure onset)
Have the same experimenter/technician handling the animal regularly
If  possible, group house animals
Wild running or jumping: risk of
injury
Low Design enclosure to minimise risks of damaging collisions
Persistent seizures with difﬁculty
drinking/eating
Very low for most models Treat with anticonvulsant (intraperitoneal injection of diazepam) Animals euthanised if there is no response
from treatment within 15 min
Administration of
pharmaceutical
substances, viral vectors,
labelling substances
Depressed consciousness and
cardiorespiratory depression
Low to high, depending on
the substance
Maintain body temperature
Hydration with ﬂuid replacement via intraperitoneal, oral or
subcutaneous route
Nursed until walking and drinking
Repeated behavioural
assessment (motor,
cognitive motivational)
Not restricted to epilepsy
models
Risk of animal falling during
Rotarod assessment
High Provide padding to break the fall
Loss  of bodyweight due to
withholding of feed.
High Provide animals with a special palatable diet (gels, nuts)
Weigh animals daily (twice daily)?
Bodyweight below 85% of the weight at entry
to protocol or below 85% of the weight that is
normal for species, strain, sex and age
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.1. Models dependent on initial SE
Most common methods of inducing experimental models of
emporal lobe epilepsy use an initial period of SE, which carries
igniﬁcant risks of mortality (e.g. early versions of these models
aving mortality rates of up to 60%) (Curia et al., 2008). Much effort
as been devoted to reducing mortality during and immediately
fter SE. One common reﬁnement is to control the duration of SE, or
t least the convulsive consequences of SE, using appropriate anti-
onvulsant drugs; reducing the duration of SE has been shown to
educe mortality (Curia et al., 2008). Another is to deliver additional
are following SE to ensure that animals maintain sufﬁcient intake
f food and water, and maintain their body temperature; adopting
ppropriate welfare protocols has been shown to increase survival
p to 70% (Longo et al., 2003).
Pilocarpine-induced SE: The pilocarpine model is a widely used
odent model of temporal lobe epilepsy (Curia et al., 2008). Many
odiﬁcations of the model exist which have been driven not only
y the aims of the experiment but also by problems such as high-
ortality rates and the reliability of seizure induction. It is therefore
 good example of how models can be reﬁned. The efﬁcacy and mor-
ality of the pilocarpine model has been reviewed in some detail
nd various research groups have modiﬁed protocols by using dif-
erent doses of pilocarpine (Longo et al., 2003), titrating pilocarpine
o the individual seizure threshold by giving several low doses,
re-treatment procedures, animal strain and species (Curia et al.,
008). The pilocarpine model (at 300–400 mg/kg) is associated with
ortality rates around 30–55% for male Wistar rats, but can be
ower for Sprague-Dawley rats (Turski et al., 1983, 1989; Cavalheiro
t al., 1991; Liu et al., 1994; Esclapez et al., 1999; Curia et al.,
008). Peripheral cholinergic effects (pilocarpine causes changes in
ardiovascular function, excessive salivation, diarrhoea and dehy-
ration) can be antagonised by subcutaneous administration of
 mg/kg methyl scopolamine 30 min  before injection of pilocarpine.
he side-effects of anticholinergic agents can include drying of the
ucus membranes, and reduction in tear formation; use of ocular
ubricants (e.g. “liquid-tears”) can reduce the impact of the latter
roblem. Increasing general hydration state by ﬂuid therapy (by
outh or parenterally) can also be beneﬁcial. When implementing
hese interventions it may  be important to apply them to control
roups also. After a deﬁned duration of SE (time period should be
djusted to research aim and protocol, e.g. 40–60 min) administra-
ion of 8–20 mg/kg diazepam with or without ketamine (Martin and
apur, 2008) can be used to decrease the severity of behavioural
eizures, reduce seizure severity, and reduce mortality rates. Glu-
ose depots can be injected subcutaneously 1 h following diazepam
reatment to help animals to recover faster from SE. This can be
urther reﬁned by titrating pilocarpine to the individual seizure
hreshold by giving several low doses of pilocarpine, which has
een shown to also efﬁciently produce SE and subsequently chronic
pilepsy with lower mortality rates than the aforementioned pilo-
arpine models (Glien et al., 2001). The mortality with this approach
an be further improved when rodents are given a central muscle
elaxant (xylazine) reducing the severity of the convulsions but not
ffecting electrographic seizures (Yang et al., 2006). Mortality and
uffering can be further reduced by optimising perioperative care.
Kainic acid-induced SE: Systemic kainic acid induces SE and
an be associated with high mortality in adults. Mortality in adult
ats has been reduced by administering kainic acid in several small
oses, repeated every 30–60 min, until each rat reached SE (Hellier
nd Dudek, 2005). This approach reduced mortality to 15% while
chieving spontaneous seizures in 98% of animals. Tailoring the
ose to individual rats avoids the most sensitive rats being at risk of
eath and the least not developing chronic epilepsy. Experimental
nduction methods may  result in a sub-population of animals that
o not show an obvious epileptic phenotype.nce Methods 260 (2016) 2–25
Electrical stimulation-induced SE: SE can also be induced by
electrical stimulation of the brain. As with other models dependent
on initial SE, the duration of a self-sustaining SE can be terminated
by drugs. If SE is not self-sustaining then stimulation can be ter-
minated, both to control duration and limit “explosive” running or
jumping that could result in injury to the animal or damage to the
head-stage.
4.2. Models not involving SE
Chronic epilepsy can be induced by methods that do not cause
SE. One is tetanus toxin injected into the hippocampus or neocor-
tex, both of which result in spontaneous seizures, usually after a
latent period of a few days to a week or two. Dose matters: 1000
minimum lethal doses (MLD) proved lethal to 7/10 rats (Bagetta
et al., 1990), while 6–12 MLD  had no mortality and induced reliable
epileptic seizures (Mellanby et al., 1977). One complication is that
toxicity can vary between batches, with both production and trans-
port having an impact; duration and conditions of storage also may
lead to loss of toxicity. Ideally the whole toxin should be assayed
before use, but local regulations may  not permit in vivo assays.
Traumatic brain injury (TBI): In humans the risk of epilepsy
after TBI depends on its severity, ranging from about 4% (mild
TBI) to 53% (penetrating injury) (Annegers et al., 1998). Over the
past 40 years, a large number of models of TBI have been devel-
oped to investigate the pathologies caused by TBI and mechanisms
of consequent recovery (Xiong et al., 2013). Only recently, inten-
sive EEG monitoring studies have been conducted to determine
if animals with TBI also develop epilepsy. The most commonly
investigated models are controlled cortical impact (CCI) and ﬂuid-
percussion injury (FPI). Depending on the injury severity and
genetic background, epilepsy develops in up to 50% of animals,
even though some investigators have reported occurrence of spon-
taneous seizures in 100% of animals (D’Ambrosio et al., 2004;
Pitkänen and Immonen, 2014). Acute (<48 h) mortality depends on
the injury severity, (e.g. 30% after severe TBI), relating to increased
intracranial pressure. Even though acute seizures can occur in >30%
of animals, seizure- or SE-related mortality have not been reported
at acute post-TBI phase. Compared to SE models, the frequency of
late (>1 week post-TBI) spontaneous seizures is much lower. Acute
post-injury care should focus on treatment of possible skin irrita-
tions or infections around craniotomy, follow-up of weight, ﬂuid
balance (animals can have severe hemiparesis during the ﬁrst two
weeks post-injury) and maintenance of body temperature. When
animals are implanted with electrodes, the same follow-up proce-
dures apply as in other models (Table 5).
Absence models: The most commonly used models of absence
seizures are the polygenic inbred Genetic Absence Epilepsy Rats
from Strasbourg (GAERS) (Danober et al., 1998), Wistar Albino
Glaxo/Rijswijk (WAG) rats, (Van Luijtelaar and Zobeiri, 2014) and
the spontaneous monogenic mutant mice stargazer, tottering and
lethargic (Maheshwari and Noebels, 2014). Many mouse strains are
listed in the Jackson Laboratory database as showing an absence
phenotype, and genetic manipulations of voltage- and transmitter-
gated channels have been reported to lead to the expression of
spike-and-wave discharges (Maheshwari and Noebels, 2014). In
contrast to human absence, however, both rodent models have
a higher frequency of spike-and-wave discharges and seizures
persist for their entire life span. Absence seizures carry minimal
adverse effects and are thus in general kept under standard hus-
bandry conditions; nor have they been reported to express any
adverse behavioural signs of suffering even after 1 or 2 years with
absences. In many cases, data is unavailable on the co-expression of
the behavioural components (i.e. immobility, vibrissae twitching,
etc.) of absence seizures in rodents. Spontaneous mutant mouse
models may  carry additional behavioural phenotypes (e.g. mild
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o moderate ataxia) which may  become an issue, in particular
fter implantation of intracranial electrodes or other intracere-
ral devices. Increased anxiety and depression-like behaviour have
een reported in WAG  and GAERS rats, suggesting the presence of
omorbidity in these rat absence models (Jones et al., 2008; Van
uijtelaar, 2011; Epps and Weinshenker, 2013).
Genetic models: Increasingly, genetically-modiﬁed animals are
sed in epilepsy research (Fig. 1) and the number of identiﬁed
uman epileptogenic mutations and genes is rising at an accel-
rated pace (Guerrini et al., 2014). Besides spontaneous mutant
nimals identiﬁed by phenotypic screening, genetic modiﬁcations
an be generated by transgenesis, chemical mutagenesis or gene
argeting (Mantegazza et al., 2010). Transgenic models may  not
eproduce real pathophysiological conditions as accurately as other
odels (even if there are exceptions, e.g. Peters et al., 2005), but
hey are relatively easy to generate and not very expensive, allow-
ng small-scale screening of mutants. Chemical mutagenesis can
e used within a phenotype-driven strategy (forward genetics)
n order to generate animal models of epilepsy; this generates a
arge number of mutant mice that are screened and excluded if
hey do not show an appropriate phenotype. Gene targeting is the
est available method for accurately reproducing genetic condi-
ions, pathological conditions and phenotypes of human disease.
ecent gene targeting techniques allow the introduction of speciﬁc
utations in different species at reduced cost and time. Reﬁne-
ent opportunities for the generation, management and care
f genetically-modiﬁed animals have been reviewed elsewhere
Robinson et al., 2004). In addition to these, speciﬁc reﬁnements
elated to breeding strategies and genotyping should be considered.
. Discussion and conclusions
Animal models play a key role in epilepsy research but their
se is associated with considerable welfare cost to the animals
nvolved. As the ﬁeld of epilepsy research evolves and moves
owards studies of epileptogenesis, potentially more animals will
e used. The 3Rs principles should be considered during the design,
onduct and reporting of in vivo epilepsy research projects. Where
nimals are used, the onus is on the researcher to minimise avoid-
ble harm, for scientiﬁc and ethical reasons. The Working Group
as identiﬁed a number of opportunities for reﬁnement of the
se of rodent models of epilepsy and seizures. Implementation of
he recommendations will not only minimise animal suffering but
lso can potentially improve the quality of scientiﬁc data derived
rom the animals, therefore maximising animal use. Some adverse
ffects may  be unavoidable; in such cases, assessment of the bal-
nce between the potential scientiﬁc and medical beneﬁts of the
esearch, and the likely harms to the animals involved requires
areful consideration; a higher welfare impact requires a higher
evel of justiﬁcation.
.1. Data gaps and future research
The Working Group identiﬁed a number of research areas where
ncreased knowledge and technological development would facil-
tate reﬁnement and best practice in the use of animal models
f epilepsy and seizures. Funding opportunities are available to
ddress these data gaps (e.g. NC3Rs funding schemes: www.nc3rs.
rg.uk/funding). Developing improved approaches to understanding the expe-
riences of animals used in the study of epilepsy; in particular,
during and in between seizures and following a period of SE (see
Section 3.1).nce Methods 260 (2016) 2–25 19
 Technological advancement of electrophysiological devices with
increased biocompatibility and reliability to allow more data to
be acquired per animal (see Section 3.3).
 Automated analysis tools to allow high throughput analysis of
EEG data and maximise animal use (see Section 3.3). Telemetry
is generally preferable to tethering for long-term recordings but
this technology needs further development for greater miniatur-
isation, more channels and longer battery life.
 Video analysis tools to assist with the monitoring and classiﬁca-
tion of spontaneous seizures, to provide important information
about seizure frequency and type and to provide the context
for the interpretation of data about co-morbidities and welfare
issues.
 Increased understanding of the interactions of anaesthetic
agents and common analgesics on seizure susceptibility and
intensity so that more informed choices can be made (see Section
3.4).
 The use and relevance of seizure scoring systems with different
animal models of epilepsy and for different age groups (see Sec-
tion 3.5). The Racine’s scale and its adaptations are commonly
used but are not generalisable to all animal models of seizures
and epilepsy.
 The effects on welfare of group housing animals prone to
seizures, in particular instrumented animals (see Section 3.7).
A focused effort from the epilepsy research community to
address these research objectives could extend and provide higher
levels of evidence in support of the Working Group’s recommen-
dations and help to deﬁne contemporary best practice in this area
of research.
5.2. Recommendations
A summary of the recommendations in the report is provided
below:
1. A search of the scientiﬁc literature should be carried out to
ensure the animal model chosen is scientiﬁcally relevant, the
least severe model for the scientiﬁc purpose, and that any
model-speciﬁc reﬁnement opportunities are identiﬁed (Grade
D).
2. Assessment of the harms to animals and balancing these against
the potential beneﬁts of the research, should take account of
the lifetime experience of the animals and the whole epilepsy
syndrome (not just seizures). The greater the animal welfare
cost, the greater the strength of justiﬁcation needed in terms of
scientiﬁc and/or medical beneﬁt (Grade D).
3. Variations in the strain, genetic background, source, age and
sex of animals can inﬂuence seizure susceptibility and mortal-
ity (e.g. Grade B for strain; Schauwecker, 2011, Level II; Grade
A for age: Thompson et al., 1991, Level I, Pierson and Swann,
1988, Level I+; Grade A for sex; Scharfman and MacLusky, 2014,
Level II; Grade A for source; Borges et al., 2003, Level I). The
variability should be taken into consideration when design-
ing and conducting studies and adequate measures taken to
reduce experimental bias. The strain, source, age and sex of
animals used in studies should be consistent, and reported in
publications.
4. If using genetically-modiﬁed mice, the genetic background
should be controlled for and appropriate littermate controls
with the same genetic background should be used; for exam-
ple, use age-matched wild-type littermates as controls (Grade
A; Bourdi et al., 2011, Level I).
5. Given the evidence for sex-speciﬁc effects on epileptogenesis,
consideration should be given to using animals of both sexes.
If females are used, the impact of the oestrus cycle on seizure
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susceptibility needs to be considered (Grade A; Scharfman et al.,
2005, Level I).
6. Procedures leading to the induction of seizures and/or epilepsy
should be tailored to reach the scientiﬁc objectives effectively
whilst minimising harms and mortality (Grade D).
7. Research personnel should be adequately trained and compe-
tent in the manual skills for appropriate handling and restraint
of animals for the administration of substances. Picking up mice
by the tail should be avoided as this induces aversion and high
anxiety; animals should be picked up by a non-aversive method
(e.g. handling tunnels or cupping) (Grade A; Gouveia and Hurst,
2013, Level I+).
8. The experimental setup should be maximally effective in
delivering the research objectives while prioritising animal
welfare and minimising interference with behaviour, espe-
cially in behavioural studies where the instrumentation for
seizure recording may  impede movement and signiﬁcantly
alter behaviour (Grade D).
9. Wherever possible, radiotelemetry should be used in pref-
erence to tethered systems for chronic electrophysiological
recordings (Grade D).
0. Radiotelemetry devices should be as light as possible, con-
sistent with the scientiﬁc objectives. Consideration should be
given to the physiological conformation of the device and its
potential impact on posture and natural behaviours (e.g. eat-
ing, drinking, grooming and rearing) (Grade C; Morton et al.,
2003; Hawkins et al., 2004, Level III).
1. Good surgical practice and aseptic technique should be used,
with pain management, maintenance of body temperature,
replenishment of ﬂuids lost under anaesthesia and effective
post-operative care and consideration of antibiotic prophylaxis
(Grade D) (see recommendation 15).
2. Animals should be allowed sufﬁcient time to recover follow-
ing surgical procedures using anaesthesia, before subsequent
recordings/measurements are taken (Grade A; Culley et al.,
2004, Level I+).
3. Steps should be taken to identify, assess and alleviate pain fol-
lowing procedures requiring surgery. Appropriate pain relief
should be provided and reported in publications. Choice of anal-
gesic should be made with care based on veterinary advice and
taking into account evidence of potential interference with the
science (Grade C; Tremoleda et al., 2012, Level III).
4. Topical antibiotics should be used for simple surgical pro-
cedures and prophylactic antibiotics used for implantation
procedures if appropriate, based on veterinary advice (Grade
D).
5. A modiﬁed food source should be provided to encourage eat-
ing and prevent weight loss following surgery and/or seizure
induction (Grade A; Jedrzejko and Persinger, 2001, Level I). This
should be introduced prior to surgery to ensure familiarisation
and consumption. Food and drink should be accessible from the
ﬂoor of the cage (Grade D).
6. Each animal model of epilepsy should be assessed and an appro-
priate welfare score sheet validated by both animal care staff
and the principal investigator. The score sheet should deﬁne
when action should be taken to minimise pain, suffering and/or
distress by intervention/treatment and application of humane
endpoints. Such scoring systems should incorporate both moni-
toring of actual model induction and monitoring of the resulting
epileptic state (Grade D).
7. Animal welfare assessments should be conducted at a fre-
quency appropriate to the state of well-being and health of the
individual animal; at least on a daily basis and multiple times
per day in the immediate post-operative recovery period or
following speciﬁc interventions (Grade D).nce Methods 260 (2016) 2–25
18. A tailored approach should be adopted to assess, deﬁne and
implement humane endpoints for each experiment in order to
minimise harms, whilst allowing achievement of the scientiﬁc
objectives (Grade C; Morton, 1999, Level III). This should take
into consideration the current legal framework, scientiﬁc, justi-
ﬁable and unpredicted endpoints (see Glossary) and the results
of welfare assessments.
19. Mice and rats should be socially housed unless there are com-
pelling scientiﬁc or animal health reasons for single housing.
Each case should be carefully evaluated; weighing the welfare
beneﬁts and costs (Grade A; Võikar et al., 2005; Kalliokoski et al.,
2014, Level I).
20. Animals should be paired or grouped prior to surgery to
increase the social bond, thereby reducing the risk of adverse
behaviour towards the operated or instrumented animal(s)
(Grade D).
21. Socially housed animals should be monitored to identify signs
of aggressive behaviour and the consumption of supporting
supplementary food intended for the experimental animal
(Grade A; Mellanby et al., 1981, Level I).
22. Environmental enrichment should be provided to allow ani-
mals to express naturalistic behaviours unless there is a
justiﬁed reason to withhold it (Grade A; Koh et al., 2007, Level
I+).
23. Environmental enrichment should be consistent in the home
cage to reduce variability (Grade A; Fares et al., 2013, Level
I+). Enrichment protocols should be described carefully and
detailed in published manuscripts to allow others to adopt a
similar approach and reduce inter-laboratory variations.
24. Researchers should report their animal studies in accordance
with the ARRIVE guidelines. Journals publishing epilepsy and
seizure studies should: (a) include the guidelines in their
Instruction to Authors; (b) require authors to submit an ARRIVE
checklist with their manuscripts; and (c) encourage editors to
review the checklist (Grade D).
25. Common Data Elements (CDE) should be prepared and used to
help standardise the collection of data, including those relevant
to animal welfare, and facilitate comparison of results (Grade
D).
26. Researchers should take advantage of opportunities to make all
research studies regardless of their ﬁndings openly available
to reduce publication bias in epilepsy research (Grade A; Sena
et al., 2010, Level I+).
27. The reﬁnement opportunities framework (Table 5) should be
developed and used for each project as a tool for predicting,
recognising and ameliorating suffering and assessing sever-
ity in the particular epilepsy model being used (Grade D; EU
Severity Assessment Framework, Level IV).
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Glossary
This glossary provides deﬁnitions of terms covered in the report in context of animal
models of epilepsy and seizures. Ataxia:  Lack of ability to coordinate muscle
movements.
AWERB (Animal Welfare and Ethical Review Body): Committee responsible for
ethical review of animal research projects and local oversight of animal use in
the United Kingdom.
Catalepsy: Muscular rigidity and ﬁxity of posture.
Comorbidity: Presence of one or more additional disorders co-occurring with pri-
mary disease.
Epilepsy: Conceptual deﬁnition: a disorder of the brain characterised by an enduring
predisposition to generate unprovoked epileptic seizures and by the neuro-
biological, cognitive, psychological, and social consequences of this condition
(Fisher et al., 2005). Operational deﬁnition: (i) at least two unprovoked (or reﬂex)
seizures occurring more than 24 h apart; (ii) one unprovoked (or reﬂex) seizure
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and a probability of further seizures similar to the general recurrence risk after
two  unprovoked seizures (at least 60%) occurring over the next 10 years; and
(iii)  diagnosis of an epilepsy syndrome (Fisher et al., 2014).
pileptogenesis:  The development and extension of tissue capable of generating
spontaneous seizures, resulting in (a) the development of an epileptic condition
and/or (b) progression of epilepsy after the condition is established. Recently a
Working Group of the International League Against Epilepsy revised the termi-
nology related to the term epileptogenesis and provided recommendations for
conducting anti-epileptogenesis studies (Pitkänen et al., 2013).
ACUC (Institutional Animal Care and Use Committee): Committee responsible
for ethical review of research protocols and evaluation of institution animal
care and use in the United States and other counties.
nterictal:  The period between seizures that is characteristic of an epilepsy disorder.
ustiﬁable endpoint: Pain or suffering beyond this point would be unacceptable
and not increase the scientiﬁc yield. This is based on a harm/beneﬁt justiﬁcation
and needs to be identiﬁed and deﬁned for each experiment between scientists,
the  local ethical or animal care and use committee and regulators. If an experi-
ment causes any pain or suffering, the beneﬁts, which might be achieved by the
experiment, need to outweigh the level of expected suffering.
ydriasis:  Dilation of the pupil.nce Methods 260 (2016) 2–25 25
NSAIDs (non-steroidal anti-inﬂammatory drugs): A class of analgesics that act by
inhibiting enzymes associated with prostaglandin and leukotriene production,
and  so reduce pain and inﬂammation.
Ocular keratitis: Inﬂammation in the cornea.
Ptosis:  Drooping or falling of the eyelid.
Scientiﬁc endpoint: The point when the objective of the experiment has been
achieved and any suffering beyond this point should be avoided, as there is
no  further scientiﬁc gain (Morton, 1999). The scientiﬁc endpoint needs to be
ethically justiﬁable and falls within the limits of permissible suffering (Ashall,
2014).
Seizure:  The transient occurrence of signs due to abnormal excessive or synchronous
neuronal activity in the brain (Fisher et al., 2005).
Status epilepticus: A prolonged seizure usually lasting more than 30 min. The dura-
tion of SE should be reported in publications.
Straub tail: Abnormal posture and rigidity of the tail.
Unexpected endpoint: Either suffering which is more severe than anticipated at the
outset of the experiment or unexpected because of an unrelated illness, accident
or  non-anticipated adverse effect. This can occur following an unrelated illness,
accident or through unexpected adverse effects of the experiment, these are not
considered in the cost/beneﬁt justiﬁcation (Ashall, 2014).
